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ABSTRACT 
The skin is colonized with a wide range of microbes. Some offer vital protection from colonization 
and infection with pathogenic strains while others have the capacity to cause or exacerbate disease. 
The aim of this thesis was to investigate the role and management of microbes found on skin 
affected by three disorders; balanoposthitis, impetigo and atopic dermatitis (AD).  
 
Paper I investigates the frequency and distribution of bacteria, Candida and Malassezia species in 
balanoposthitis, a common inflammatory and/or infectious disorder of the prepuce and glans penis. 
Patients with balanoposthitis were colonized with microbes more often than a control group. 
Specifically, S. aureus was found in 19% of patients with balanoposthitis and not at all in the 
control group. There was no significant increase of Candida species in balanoposthitis. Different 
clinical manifestations did not predict the presence of specific microbes. There was no association 
with seborrhoeic dermatitis or psorisasis.                                                                                                       
Paper II describes the bacterial spectrum and proportion of fusidic acid-resistant S. aureus (FRSA) 
in cultures from lesional skin in impetigo and secondarily infected AD. S. aureus was the most 
frequent finding (76-93%) and fusidic acid-resistance was found in 75%, 32% and 6.1% of S. 
aureus isolates from patients with bullous impetigo, non-bullous impetigo and secondarily infected 
AD, respectively. 
In paper III the in vitro antimicrobial activity of topical skin pharmaceuticals was tested against S. 
aureus, S. epidermidis, Streptococcus pyogenes, Escherichia coli and Candida albicans. 
Formulations with clioquinol, halquinol and hydrogen peroxide had a broad antimicrobial effect. 
The azole class of antifungal formulations had an anti-staphylococcal effect. 
Paper IV describes the variations in S. aureus colonization in relation to the severity of AD 
(assessed with SCORAD) in adult patients during a 5-month follow-up. High density of S. aureus 
on lesional skin, colonization of multiple body sites and persistent colonization with one strain was 
associated with more severe disease. 
 
Conclusion: Balanoposthitis was associated with increased colonization with potentially 
pathogenic microbes. The primary therapeutic target in mild to moderate cases without overt signs 
of infection should be to decrease inflammation and microbial load with a topical corticosteroid-
antimicrobial combination. FRSA were a common cause of impetigo but remained relatively 
infrequent in secondarily infected AD. Use of topical fusidic promotes the spread of resistant strains 
and should be avoided. Topical non-resistance-promoting antiseptic formulations could be useful in 
the management of superficial skin infections and help reduce the use of systemic antibiotic 
treatment. Detailed investigation of different aspects of S. aureus colonization in relation to AD 
severity can increase understanding of the complex S. aureus-AD interaction and the possible value 
of anti-staphylococcal interventions in clinically non-infected AD.  
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ABBREVIATIONS 
 
AD Atopic dermatitis 
C. albicans Candida albicans 
CA-MRSA Community-associated methicillin-resistant S. aureus 
CFU Colony-forming unit 
Clioquinol  5-chloro-7-iodo-8-quinolinol  
CoNS Coagulase-negative staphylococci 
DMF Dimethylformamide  
E. coli Escherichia coli 
EEFIC Epidemic European Fusidic acid-resistant Impetigo Clone 
EF-G Elongation factor G 
FLG Filaggrin 
FRSA Fusidic acid-resistant S. aureus 
Halquinol 5,7-dichloro-, 5-chloro- and 7-chloro-8-quinolinol mixture 
MIC Minimal inhibitory concentration 
MRSA Methicillin-resistant S. aureus 
PBP Penicillin-binding protein 
PBS Phospate-buffered saline 
PFGE Pulsed-field gel electrophoresis 
PVL Panton-Valentine leukocidin 
S. aureus Staphylococcus aureus 
S. epidermidis Staphylococcus epidermidis 
S. pyogenes Streptococcus pyogenes 
SCORAD  Severity SCORing of Atopic Dermatitis 
SSSS Staphylococcal scalded skin syndrome 
SSTI Skin and soft tissue infection 
TSST-1 Toxic shock syndrome toxin-1 
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INTRODUCTION 
 
Microbes are everywhere. We tend to think of them as causes of disease and decay and have, in 
vain, invented numerous ways to abolish them from our lives. In reality, humans live in harmony 
with many microbes, are struck with disease by some and benefit from others. For instance, the 
commensals of the human nasopharynx, skin and gut are crucial for bacterial homeostasis, 
preventing colonization and infection with pathogenic strains. Staphylococcus aureus, a potentially 
pathogenic bacteria which will be discussed in further detail in this thesis, can cause a wide range of 
different diseases, such as impetigo, other skin and soft tissue infections (SSTIs), staphylococcal 
scalded skin syndrome (SSSS), endocarditis and food poisoning [1]. Bacterial fermentation 
produces the desired consistency and flavour of yoghurt and cheese [2, 3]. The carbon dioxide 
produced by fungi makes dough rise in breadmaking and their metabolic activity on the juice of 
grapes provide the unique taste of wine [4]. 
 
The work presented in this thesis was aimed at investigating the role and management of microbes 
found on skin affected by three different skin disorders; balanoposthitis, impetigo and atopic 
dermatitis (AD).   
The study of balanoposthitis presented in paper I was prompted by the lack of a comprehensive 
description of the spectrum of microbes found in this particular skin disease. Specifically, there 
were no reports of the frequency and distribution of Malassezia species in balanoposthitis. The 
Malassezia yeasts cause seborrhoeic dermatitis, a skin disease that, not unlike balanoposthitis, is 
associated with erythema, papules and scales in areas where sebaceous glands are abundant.  
A Scandinavian outbreak of bullous impetigo caused by a strain of S. aureus resistant to the topical 
fusidic acid preparations which were widely used at the time inspired the next study. The frequency 
of fusidic acid-resistant S. aureus (FRSA) in patients with impetigo attending the Department of 
Dermatology at Sahlgrenska University Hospital in 2004-2008 was investigated. In addition, the 
frequency of FRSA in patients with atopic dermatitis (AD), a group of patients who are highly 
prone to colonization and infection with S. aureus, was recorded during the same time period. The 
results are presented in paper II.  
As demonstrated by the emergence of FRSA it is vital for each clinician to use antibiotics sensibly. 
Antibiotic resistance is a rapidly increasing global health care problem. SSTIs are common 
conditions and treatment with topical antiseptic preparations can sometimes be an alternative to oral 
antibiotics. In paper III the in vitro antimicrobial properties of currently available topical skin 
pharmaceuticals were tested with the agar dilution assay.  
Clinical experience suggests that there is a positive correlation between skin colonization with S. 
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aureus and disease severity in patients with AD. Patients with severe AD experience improvement 
when treated with antibiotics, even in the absence of flare-ups. Despite this there is no convincing 
scientific data demonstrating an effect of anti-staphylococcal treatment in clinically non-infected 
AD [5]. One way to investigate a possible connection between S. aureus colonization and severity 
of clinically non-infected AD is to monitor the properties of colonization and disease intensity over 
time. In paper IV the variation in AD severity in adult patients during a 5-month follow-up was 
described and related to changes in S. aureus colonization. 
 
The introduction of a thesis should give a theoretical back-drop for the topics which are about to be 
discussed. Therefore, the introductory part of this body of work is focused on describing the key 
players in the microbial drama that is played out on, and in, the skin. The leading character is the 
multi-talented S. aureus. However, without supporting actors there would be no plot so the 
Malassezia species, Candida albicans, S. epidermidis and Streptococcus pyogenes are also 
presented in some detail.  
The epidermal stage is vast and complex and also deserves some mentioning. Sometimes the floor 
boards cannot be trusted, fragile due to mutations of structural proteins such as filaggrin in AD.  
The plot and manuscript of our plays, and by that we mean the pathogenesis and current treatment 
guidelines for balanoposthitis, impetigo and AD, will be reviewed. The mode of action for fusidic 
acid and selected antiseptics will also be covered before we move on to discuss papers I-IV. 
 
So please, take a seat! Curtain up! Enjoy! 
 
Mikael Alsterholm 
Gothenburg, 17th of October 2012 
 
 
 
Photo: Mikael Alsterholm 
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THE MICROBES 
 
COLONIZATION AND INFECTION 
 
Colonization 
Colonization is characterized by the presence of microbes in a host where those microbes do not 
disrupt the normal body functions of that host. Colonization usually occurs on surfaces in contact 
with the surrounding environment, i. e. the skin, the mucous membranes of the nasal and oral 
cavities, urogenitalia, and the gastrointestinal mucosa [6]. Colonizing microbes can be commensals 
as well as symbionts. Commensals live closely together with their host and benefit by the 
relationship whereas the host neither benefits nor is harmed. Symbionts are organisms that live 
together and where the relationship is of mutual advantage [4]. The term commensal is, somewhat 
incorrectly, often used as a synonym to colonizing microbial flora. When the term is used in this 
thesis it will be in this referred meaning.  
 
Infection 
Infection is defined as an invasion of the host by microbes that can cause pathological conditions or 
diseases [7]. 
 
 
 STAPHYLOCOCCUS AUREUS 
 
Physiology and structure 
The members of the genus Staphylococcus are spherical, gram-positive bacteria which can be found 
on the skin and mucous membranes of humans, other mammals and birds [4]. They are facultative 
anaerobes, meaning that they have the ability to generate energy by aerobic as well as anaerobic 
respiration, the latter yielding lactic acid.  The name Staphylococcus is derived from the Greek term 
staphylé which means “a bunch of grapes” and refers to the growth pattern of the staphylococci [4]. 
Currently, the genus Staphylococcus consists of approximately 40 species [8].  
S. aureus is the most virulent of the staphylococci. It is a highly versatile and adaptable spherical 
bacteria with a diameter of about one µm [1]. The colonies of S. aureus are golden because of 
carotenoid pigments that form during growth [9]. Staphylococci produce catalase, an enzyme which 
catalyzes the conversion of hydrogen peroxide to water and oxygen. This ability is used to 
differentiate them from gram-positive, catalase-negative cocci such as the streptococci. S. aureus 
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also produces coagulase which interacts with prothrombin leading to blood clotting by the 
conversion of fibrinogen to fibrine. The coagulase test is used to distinguish between S. aureus and 
other staphylococci in clinical laboratories since S. aureus is the only Staphylococcus species found 
in humans that produces coagulase [4]. In other words, S. aureus can promote the conversion of 
fibrinogen to fibrin in a test tube whereas other clinical Staphylococcus isolates cannot. Therefore, 
all other members of the Staphyloccocus species found in humans (for instance S. epidermidis and 
S. saprophyticus) are collectively referred to as coagulase-negative staphylococci (CoNS). 
  
The cytoplasm of S. aureus is encapsulated by a cytoplasmic membrane comprised of proteins and 
lipids, a cell wall and sometimes a polysaccharide slime layer. The latter is believed to inhibit 
chemotaxis and phagocytosis by polymorphonuclear leukocytes as well as help S. aureus to adhere 
to synthetic materials. Not all clinical isolates of S. aureus are able to produce a slime layer, reports 
range from 45-70% [10, 11]. Bacterial populations enclosed in a polysaccharide slime layer are 
referred to as biofilm. 
The principal component of the rigid S. aureus cell wall is peptidoglycan, which consists of peptide 
cross-linked glycan chains. Teichoic acid is attached to the peptidoglycan of the cell wall. Teichoic 
acid aids the binding of S. aureus to fibronectin of mucosal surfaces. Another component of the S. 
aureus cell wall is bound coagulase, discussed above. In addition, several virulence factors such as 
adhesins are linked to the cell wall. These and other virulence factors are discussed below. 
 
S. aureus can cause a wide range of diseases and is one of the most studied bacterial pathogens. At 
the same time it can also reside on the skin and mucous membranes of humans as a commensal. The 
anterior nares is the most frequent carriage site for S. aureus. Longitudinal studies show that about 
20% of individuals are persistent S aureus carriers in the anterior nares, 30% are intermittent 
carriers and 50% non-carriers [12-16]. The frequency of carriage on different body sites ranges 
from 10-20% in the general population and from 40-90% in nasal carriers. Nasal carriage increases 
the risk of developing a S. aureus infection [13, 17].  
 
Virulence factors 
S. aureus produces a plethora of virulence factors making it a very powerful pathogen. It can cause 
infections of the blood, skin, soft tissue, bone and lower respiratory tract. The virulence factors 
produced by S. aureus include adhesins, exotoxins and superantigen toxins.  
The complete genome of two methicillin-resistant strains of S. aureus (MRSA) was first sequenced 
in 2001 [18]. In addition to coding segments for previously known virulence factors the sequencing 
revealed an array of genes coding for other possible toxins and adhesins, meaning that the 
15 
 
pathogenic potential of S. aureus is still not realized in full.  
Another extremely important aspect of the “success” of S. aureus as a pathogen is a remarkable 
ability to become resistant to antibiotics. 
 
Adhesins 
S. aureus expresses several microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMS).  The function of the MSCRAMMS is to help S. aureus bind to the tissue of its 
host. 
Fibronectin binding proteins A and B mediate the attachment of S. aureus to fibronectin, an extra-
cellular matrix component. This mode of binding is believed to be important for the colonization of 
atopic skin where fibronectin is redistributed to the cornified layer [19]. Collagen binding protein, 
(Cna) is needed for the attachment of S. aureus to collagen and cartilage [20]. Clumping factors A 
and B (ClfA and ClfB) mediate, as revealed by their names, clumping but also help S. aureus adhere 
to fibrinogen when fibronectin is present. This mechanism is thought to be of importance in wound 
infections [21].  
Protein A is covalently linked to the peptidoglycan layer of the cell wall of most S. aureus strains 
but not to the cell wall of the CoNS. It binds the Fc-receptor of IgG1, IgG2 and IgG4, thereby 
preventing opsonization and phagocytosis of S. aureus by the cells of the immune system [1, 4]. 
Further protection from the immune system as well as from antibiotics and antiseptics can be 
provided by the formation of the polysaccharide slime layer and biofilm, a mechanism which can be 
considered an adhesin-related virulence factor. 
 
Exotoxins 
S. aureus can secrete numerous toxins which form pores in the cytoplasmic membranes of host cells 
and cause subsequent cytolysis. Alpha-, beta- and gamma-hemolysins, leukocidin and Panton-
Valentine leukocidin (PVL) are all examples of exotoxins. PVL is a virulence factor of community-
associated MRSA (CA-MRSA) and consists of two proteins (LukF-PV and LukS-PV) that hetero-
oligomerize in the host´s cytoplasmic membrane to form a pore. The main target of PVL is 
leukocytes which in part explains the ability of CA-MRSA to cause necrotizing pneumonia and skin 
infections [22]. 
The exfoliative toxins of S. aureus (exfoliative toxins A (etaA) and B (etaB)) are serine proteases 
that cause the epidermal blistering of bullous impetigo and SSSS.  The toxin cleaves desmoglein 1, 
a structural protein of the desmosome which holds the keratinocytes in junction [23]. In bullous 
impetigo the toxin is produced locally at the site of infection whereas in SSSS the toxin circulates 
and produces blisters and desquamation at multiple body sites. 
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Superantigen toxins 
While adhesins help S. aureus to colonize and infect cells and exotoxins target host cells and 
immune cells with different affinity, the superantigen toxins have a different mode of action. 
Superantigen toxins crosslink MHC class II molecules on antigen-presenting cells with T-cell 
receptors. This connection induces antigen-independent T-cell proliferation and cytokine release 
which in turn causes capillary leak and hypotension. Examples of superantigen toxins are toxic 
shock syndrome toxin-1 (TSST-1) and the enterotoxins A, B, C, D, E, G and Q. TSST-1 causes toxic 
shock syndrome, a potentially fatal condition characterized by fever, hypotension, macular rash and 
desquamation [24]. The enterotoxins, which cannot be hydrolysed by intestinal enzymes and are 
stable at 100°C for up to 30 minutes, cause staphylococcal foodborne disease [4].  
 
In paper IV we have studied the pattern of colonization with S. aureus, a powerful pathogen as well 
as a commensal, in relation to disease severity in adult patients with AD during a 5-month follow-
up.  
 
Resistance to antibiotics 
During the antibiotic area S. aureus has proven to be highly skilled at developing resistance. In the 
mid 1940s, just a few years after the introduction of penicillin in clinical practice, penicillin-
resistant S. aureus strains were found in hospitals [25, 26]. These strains produced a penicillinase 
which hydrolysed the β-lactam ring of penicillin. Within a decade penicillin-resistant S. aureus 
strains were pandemic [27]. In the late 1950s methicillin, a new β-lactam antibiotic, was introduced 
and in 1961 the first report of methicillin-resistant S. aureus (MRSA) was published [28]. 
Methicillin-resistance is broad and confers resistance to all β-lactam antibiotics (penicillins, 
cephalosporins and carbapenems). The mode of action for β-lactam antibiotics is to bind to 
penicillin-binding proteins (PBPs) in the bacterial cell wall and inhibit transpeptidation of glycan 
chains. The genetic basis for methicillin-resistance is the large mobile genetic element 
staphylococcal cassette chromosome mec (SCCmec). The SCCmec contains a coding sequence for 
an alternative penicillin-binding protein called PBP2a. PBP2a has low affinity for all β-lactam 
antibiotics. Therefore, β-lactam antibiotics cannot bind PBP2a and inhibit the transpeptidation of 
glycan chains. The origin of SCCmec is unknown and so is its mode of transmission. 
Until the late 1970s reports of MRSA strains remained relatively rare and confined to hospitals in 
Europe and the United States [27]. The last years of that decade and the first half of the 1980s gave 
rise to a pandemic of MRSA in hospitals. The only remaining antibiotic effective against these 
strains was vancomycin. Predictably, the increased use of vancomycin resulted in vancomycin-
resistant S. aureus strains (VRSA) [29]. Since the mid 1990s MRSA have become widespread in the 
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community on a global scale, the so-called CA-MRSA. CA-MRSA can cause fatal systemic 
infections but are also a frequent cause of necrotic SSTIs in dermatology out-patients [30-32]. 
Further testament to the ability of S. aureus to develop resistance to antibiotics is the novel clone of 
fusidic acid-resistant S. aureus (FRSA) which was discovered in epidemics of bullous impetigo in 
Sweden and Norway at the turn of the millenium. In paper II we have investigated the frequency of 
FRSA in impetigo and secondarily infected AD and we discuss the future implications of our 
findings. 
 
 
 
Figure 1. S. aureus on blood agar plate. 
Photo: Mikael Alsterholm 
 
 
STAPHYLOCOCCUS EPIDERMIDIS AND OTHER COAGULASE-NEGATIVE STAPHYLOCOCCI 
 
Physiology and structure 
S. epidermidis colonizes all humans and is the most common coccus on human skin. It can be found 
on all body sites, especially in intertriginous areas. S. epidermidis is a member of the normal skin 
flora together with S. aureus, S. saprophyticus, Micrococcus luteus, M. roseus, M. vaians (all 
aerobic cocci), Corynebacterium minutissimum, C. lipophilicus, C. xerosis, C. jeikeium, 
Brevibacterium epidermidis (aerobic coryneform bacteria), Propionibacterium acnes, P. 
granulosum, P. avidum (anaerobic coryneform bacteria), Acinetobacter spp. (gram-negative 
bacteria) and Malassezia species [33]. S. epidermidis and S. saprophyticus belong to the CoNS. 
Another 16 species within the CoNS subset have been isolated from humans [8]. Colonization with 
S. epidermidis and other CoNS is believed to play an important role for microbial homeostasis on 
the skin, competing with S. aureus and other potentially harmful microbes [34]. 
In addition to being commensals on human skin, the CoNS are important nosocomial pathogens, 
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often multidrug-resistant and have become disseminated worldwide.  S. epidermidis is the best 
studied species of the CoNS with regards to antibiotic resistance, virulence factors and pattern of 
dissemination. In contrast with the “aggressive” S. aureus which produces numerous cytolytic 
exotoxins and superantigen toxins, S. epidermidis has a much less confrontational approach. Once it 
passes a disrupted skin barrier (for instance a surgical incision) it evades the immune system, 
primarily by biofilm formation [34].  
S.  epidermidis has long been known to cause endocarditis and infections related to synthetic 
implantable devices such as prosthetic heart valves and joints, vascular grafts and intravascular 
catheters [8]. S. saprophyticus, frequently isolated from the perineal region causes urinary tract 
infections in women [35]. S. epidermidis and other CoNS are, second only to S. aureus, the most 
common cause of surgical site infections [36]. Many of the isolates of S. epidermidis from hospital-
acquired infections are methicillin-resistant and have the capacity to produce biofilm. Taken 
together, S. epidermidis infections present a therapeutic challenge since the site of infection is often 
remote and associated with a synthetic object where these frequently multidrug-resistant microbes 
form biofilm. 
 
S. epidermidis and skin disease 
On the surface, S. epidermidis lives in harmony with its host, balances the epithelial microbial flora 
and rarely causes skin disease. However, if the epithelial barrier is passed, the pathogenic potential 
can be revealed as just exemplified [37]. 
 
In paper III we have tested the antimicrobial activity of topical skin pharmaceuticals against a panel 
of microbes which are commonly found on the skin either as commensals, pathogens or both. S. 
epidermidis was part of that panel.   
 
 
MALASSEZIA SPECIES 
 
Physiology and structure 
The Malassezia yeast is a unicellular eukaryotic organism belonging to the microbial flora of the 
skin. It ranges in size from 1-8 µm in diameter and has a thick multilayered cell wall mainly 
consisting of carbohydrates, proteins and lipids. The yeast cells reproduce by unilateral budding and 
can assume various shapes such as bottle-shape, globose, ovoid or cylindrical [38]. They colonize 
the skin of humans and animals, including hair follicles, with a particular preference for sebum-
containing skin sites. 
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The taxonomy and identification methods for Malassezia species are continuously being revised as 
new species are discovered. A revision and enlargement of the genus was performed in 1996, by 
then including seven species; M. furfur, M. pachydermatis, M. sympodialis, M. globosa, M. obtusa, 
M. restricta and M. slooffiae [39]. 
In recent years, the knowledge of the genus Malassezia has expanded further and, to date, includes 
an additional seven species that have been isolated from healthy and diseased human and animal 
skin (M. dermatis, M. japonica, M. nana, M. yamatoensis, M. equina, M. caprae and M. cuniculi) 
[40]. 
With the exception of M. pachydermatis, the Malassezia species need lipids to grow in vitro. The 
differentiation of Malassezia species in clinical settings and in epidemiological studies has 
traditionally been based on morphology in combination with physiological properties (page 49) [38, 
41, 42]. Now, an option in epidemiological studies is the identification and quantification of 
Malassezia DNA from skin specimens. 
 
Malassezia and skin disease 
Malassezia species are associated with several common skin diseases such as pityriasis versicolor, 
seborrhoeic dermatitis and dandruff. 
Pityriasis versicolor is characterized by small hypo- or hyperpigmented scaly plaques, primarily 
located to seborrhoeic areas of the skin such as the chest, back and neck. High temperature and 
humidity, genetic predisposition and poor immune status are factors contributing to the disease. In 
Sweden, prevalence rates are 0.5% for males and 0.3% for females [43]. Microscopy of scales from 
pityriasis versicolor lesions reveals the presence of abundant Malassezia spores and hyphae whereas 
Malassezia are much more rarely found on unaffected skin or on the skin of healthy controls [44, 
45]. In addition, the hyphal state appears to play an important role in the pathogenesis of pityriasis 
versicolor, since hyphae are found in lesions irrespective of which Malassezia species is isolated 
[40]. M. globosa is the species that is most often isolated from pityriasis versicolor. However, while 
the association between pityriasis versicolor and Malassezia is considered confirmed, current 
epidemiological data does not permit any definitive conclusion as to which of the Malassezia 
species are implicated in this disease [40]. 
Seborrhoeic dermatitis is a relapsing skin disease with erythema and scaling in the seborrhoeic areas 
of the skin. The disease has a predilection for the scalp, eyebrows and paranasal folds but can also 
affect chest, back, axillae and genitals. Prevalence rates are reported to be 2.6% for men and 3.0% 
for women [46]. Seborrhoeic dermatitis is believed to be caused by a nonspecific immune response 
to Malassezia but the exact mechanism remains obscure [40, 47]. Dandruff is the mildest 
manifestation of seborrhoeic dermatitis.  
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In paper I we have investigated a possible role for Malassezia in balanoposthitis, a common form of 
dermatitis affecting the area of the prepuce and the glans penis where several infectious agents have 
been implicated. The frequency and distribution of Malassezia species in the male genital region 
was investigated previously in both uncircumcised and circumcised men but not in relation to 
balanoposthitis. It was concluded that Malassezia species belong to the resident microflora of the 
male genital region. Isolation rates were lower in circumcised men [48, 49]. The involvement of 
Malassezia species in skin diseases affecting the male genital region such as balanoposthitis, 
seborrhoeic dermatitis and psoriasis was suggested but not further investigated [49]. 
 
 
CANDIDA ALBICANS 
 
Physiology and structure 
Like S. aureus and the Malassezia species, the ubiquitous yeasts of the Candida species can be 
human pathogens as well as commensals. C. albicans is the most important member of its genus. 
The cytosol contains a nucleus, ribosomes, mitochondria and an endoplasmatic reticulum. The cell 
membrane consists of phospholipids, glycoproteins and, importantly, ergosterol. Ergosterol is the 
target of many antifungals because human cells contain cholesterol instead of ergosterol. Exterior to 
the cellmembrane is a cell wall containing chitin.  
C. albicans is part of the normal flora of the oral cavity, gastrointestinal tract and external genitalia 
[4, 50]. It is likely that most individuals experience at least one episode of candidal disease in their 
lifetime. Finding a Candida species in a swab sample doesn´t immediately qualify it as a relevant 
pathogen. The clinical context has to be carefully evaluated. Erythema, pustules or other signs of 
inflammation at the sample site makes clinical relevance of the finding more likely.   
 
C. albicans and skin disease 
C. albicans is favoured by the warm and moist microenvironment which arises at intertriginous 
sites in obesity, under diapers, due to incontinence, drooling and improperly fitted dentures. 
Conditions and illnesses which predispose for candidiasis include immunosuppression and diabetes 
mellitus. Treatment with systemic antibiotics can alter the normal flora of the skin and mucous 
membranes and thereby permit an overgrowth of Candida species. 
In dermatology, C. albicans is encountered as a pathogen in oral candidiasis, genital candidiasis, 
intertrigo, candidal paronychia and in diaper candidiasis [33]. The first consideration in treatment is 
to, whenever possible, reduce moisture and limit predisposing factors. Topical treatment 
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alternatives with azoles, nystatin or amphotericin B are available in several different vehicles which 
are chosen depending on body site [33, 50]. For oral candidiasis gel or mouth wash is a good 
option, genital candidiasis can be treated with a vaginal tablet or vaginal cream and for cutaneous 
candidiasis a cream is usually the best choice. Systemic fluconazole treatment is an important 
alternative for oral candidiasis responding inadequately to local treatment and for therapy-resistant 
or frequently recurring genital candidiasis. 
C. albicans can be a clinically relevant pathogen in the male genital region. C. albicans is found in 
swab samples from the area of the prepuce and glans penis in patients with balanoposthitis and has 
been considered the principal causing microbe of this condition [51-54].   
 
In paper I we have studied the frequency of C. albicans in balanoposthitis in relation to Malassezia 
species and bacteria. It was also included in the panel of microbes tested in paper III. 
 
 
STREPTOCOCCUS PYOGENES 
 
Physiology and structure 
The genus Streptococcus include a wide variety of different gram-positive cocci which appear 
arranged in pairs or chains. In contrast with the staphylococci the streptococci are catalase-negative. 
There are three different, not mutually exclusive, schemes for differentiation of streptococci; 
serological properties (Lancefield groupings A-H and K-V), haemolytic patterns and biochemical 
properties. Haemolysis can be complete (β-hemolysis), incomplete (α-hemolysis) or absent (γ-
hemolysis) [4]. 
S. pyogenes, also called Group A Streptococcus (GAS), are 0.5-1 µm spherical cocci that form short 
chains. In vitro they grow on enriched blood agar media. A large zone of β-hemolysis is observed 
around colonies. S. pyogenes has several virulence factors including the surface-anchored M-protein 
which forms the basis for modern serological differentiation of S. pyogenes strains. The M-protein 
mediates adhesion to host cells and resistance to opsonization and phagocytosis. Invasive S. 
pyogenes isolates are surrounded by a hyaluronic acid polysaccharide capsule which protects from 
opsonization and phagocytosis and is almost identical to human polysaccharides, further facilitating 
the evasion of the host immune response [55]. 
 
S. pyogenes and skin disease 
S. pyogenes is a common cause of pharyngitis, sometimes complicated by scarlet fever [50]. A 
couple of days after the first symptoms of pharyngitis patients develop a diffuse erythematous rash 
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on the upper chest and extremities. Circumoral pallor (sparing around the mouth) and sparing of the 
palms and soles is a common finding. The tounge is initially covered with a yellowish white 
membrane which is later shed revealing the red strawberry tongue. 
S. pyogenes is also the cause of several different SSTIs, ranging from superficial to deep [33]. 
Nowadays S. pyogenes is a rare cause of impetigo but remains a frequent cause of echtyma which 
penetrates further into the dermis. Erysipelas is by some authors (and particularly in the U.S.) by 
definition caused by S. pyogenes, whereas European authors tend to recognize S. aureus as well [50, 
56]. The list of pathogens causing cellulitis is more diverse but S. pyogenes is the most common. It 
is likely that health care professionals worldwide will have to re-evaluate the management of SSTIs 
in the years to come due to the CA-MRSA epidemic. CA-MRSA cause echtyma-like skin infections 
and in recent years outbreaks have been reported among military trainees, prisoners and athletes 
[32, 57]. 
In paper III we have tested the antimicrobial activity of topical skin pharmaceuticals against a panel 
of microbes which are commonly found on the skin either as commensals, pathogens or both. S. 
pyogenes was part of that panel.   
 
 
THE SKIN DISEASES 
 
BALANOPOSTHITIS 
 
Balanoposthitis is defined as inflammation of the skin of the glans penis (balanitis) or the glans 
penis and prepuce combined (balanoposthitis) [58, 59]. Balanoposthitis usually presents as pruritic 
or sore diffuse rubrosquamous macules. Symptoms can also be more pronounced with glazed 
erythema, pustules, erosions or even ulcers.  
 It is described that approximately 10% of men attending genitourinary medicine clinics in the U.K. 
suffer from balanoposthitis [60]. The main cause of balanoposthitis is considered to be infection, 
with particular attention given to yeasts, but bacteria have also been implicated [51-54]. A risk 
factor for developing Candida balanoposthitis is diabetes mellitus. In fact, a symptomatic infection 
with Candida in the area of the prepuce and glans penis or acquired phimosis (sometimes a 
consequence of balanoposthitis) can be an early cutaneous marker for diabetes mellitus [61, 62]. 
Interestingly, no specific microbial aetiological factor can be detected in 31-41% of patients with 
balanoposthitis [51-54]. Irritant dermatitis caused by traumitteration is one cause of balanoposthitis 
which probably explains a large proportion of those cases [60]. In fact, balanoposthitis has been 
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referred to as a combination of a biomechanical and infectious disorder where abrasive trauma from 
frequent retraction of the prepuce and genital washing creates a beneficial milieu for microbes [62]. 
Balanoposthitis seems to mainly, but not exclusively, affect men who are not circumcised [58, 63].  
There are several important differentials to the diagnosis of balanoposthitis as it is defined above.  
AD, seborrhoeic dermatitis and, perhaps more commonly, psoriasis can affect the male genitalia, 
causing a similar clinical picture. Genital involvement of pityriasis versicolor is rare but has been 
described [64, 65]. Plasma cell balanitis, sometimes referred to as Zoon balanitis, is a distinct 
clinical entity usually presenting as a solitary sharply circumscribed red plaque on the glans penis of 
middle-aged and older men. Histopathologically, plasma cells are seen. The aetiology is unknown 
[66]. Erythroplasia of Queyrat is the clinical appearance of Bowen´s disease (carcinoma in situ of 
squamous cells) of the prepuce and glans penis and can sometimes be mistaken for balanoposthitis 
of other aetiology. The condition is associated with human papilloma virus (HPV) and has a 
relapsing course with a risk of progression to squamous cell carcinoma [67]. 
 
The role of microbes 
Studies on the role of microbes as causative agents of balanoposthitis have shown differing results. 
Some authors have published data supporting the role of C. albicans (10-60% of cases) whereas 
others have detected a high frequency of group B streptococci (4-28% of cases) [51-54]. Among 
those studies, only two have included a control group to investigate the frequency and distribution 
of microbes on the glans penis and in the preputial sac of men without balanoposthitis in the same 
clinical setting [51, 52]. The carriage rate of C. albicans in the sulcus coronarius is reported to be 
14-20% in healthy men and does not seem to be influenced by circumcision [49, 68, 69].  
Several other microbes such as Trichomonas vaginalis, Gardnerella vaginalis, anaerobic bacteria, 
mycobacteria, Entamoeba histolytica, Treponema pallidum, herpes simplex virus and HPV, are 
infrequently associated with balanoposthitis [70, 71].  
Despite being a common skin pathogen, S. aureus has only been associated with balanoposthitis on 
rare occasion [52]. A possible role for Malassezia species in the pathogenesis of balanoposthitis has 
been suggested but not examined further [49]. 
 
Diagnosis and management 
In most mild to moderate cases the clinical presentation together with the patient´s history allows 
the clinician to diagnose balanoposthitis without an elaborate work-up. However, balanoposthitis is 
a descriptive term which covers inflammatory, infectious, pre-malignant and malignant disorders so 
every case should be carefully considered. 
There are no Swedish guidelines for the management 
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Effectiveness Group of the British Association for Sexual Health and HIV published an update of 
The U.K. National Guideline on the Management of Balanoposthitis [71]. Selected investigations 
from that guideline, adapted to Swedish conditions and intended to aid diagnosis in cases of 
uncertainty are summarized in the following. 
 
• A skin biopsy should always be secured if there is any suspicion of pre-malignant or 
malignant disease. 
• Whenever there is diagnostic uncertainty a sub-preputial swab for Candida species and 
bacterial culture should be undertaken. 
• Urinalysis for glucose – especially if candidal infection is suspected. 
• Polymerase chain reaction (PCR) analysis for herpes simplex virus (HSV) when appropriate. 
• PCR-analysis for Treponema pallidum in case of ulcerations. 
• Screening for sexually transmitted infections (STIs) such as Chlamydia trachomatis, 
Neisseria gonorrhoeae and Mycoplasma genitalium infection. 
• In chronic cases (especially if unresponsive to therapy) consider dermatoses such as 
psoriasis, AD or contact dermatitis. 
 
The aims of the investigation and treatment are to diagnose and treat STIs, to minimize sexual and 
urinary dysfunction and to detect and treat pre-malignant and malignant conditions. 
The patients are instructed to avoid frequent genital washing while inflammation is present. Genital 
washing should be restricted to once daily using only water and possibly a mild non-scented soap. 
Sexual intercourse can cause abrasive trauma to the prepuce and glans penis and should initially be 
avoided. 
Topical treatment with a hydrocortisone imidazole cream is generally effective in mild to moderate 
cases of irritant balanoposthitis and Candida balanoposthitis. The treatment of balanoposthitis will 
be discussed further in relation to the results in paper I (page 65-66). Balanoposthtitis is often 
relapsing and patients should be informed of this in order to improve compliance and obtain a good 
treatment result. 
On rare occasion, the presentation is dramatic with pronounced oedema, pain, oozing and crusts. 
This clinical picture has been associated with streptococcal or HSV infection and warrants oral 
antibiotic or antiviral treatment [72, 73]. Metronidazole should be chosen if there is suspicion of an 
anaerobic infection (foul smelling discharge, oedema and inflamed glands) [71]. 
 
In paper I we have investigated the frequency and distribution of bacteria and yeasts in 
balanoposthitis. A possible association between different clinical presentations and microbes and 
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with seborrhoeic dermatitis was also explored. 
 
 
IMPETIGO CONTAGIOSA 
 
Impetigo contagiosa (in the following referred to as impetigo) is a localized superficial skin 
infection which affects both children and adults but is more common in children. Impetigo exists in 
two clinical forms; non-bullous impetigo and bullous impetigo. Non-bullous impetigo accounts for 
70% of impetigo cases. It is characterized by erythematous macules rapidly evolving into short-
lived vesicles or pustules which are replaced by yellowish (honey-coloured) crusts and superficial 
erosions. Predilection sites are the face and extremities. Bullous impetigo affects the face and the 
extremities but also the trunk, the buttocks and the perineum. Lesions are initially small vesicles 
which later enlarge into superficial bullae ranging from 1 to 5 centimetres in diameter [33, 50].  
Differentials for impetigo include herpes simplex, secondarily infected AD, fungal infections, 
eczema herpeticum and, importantly, early stages of SSSS. In fact, the exfoliation seen in SSSS is 
explained by systemic dissemination of the exfoliative toxin which causes bullous impetigo. 
Children under the age of six years and immunocompromised adults can be affected by SSSS. 
 
The role of microbes 
In the vast majority of cases, non-bullous and bullous impetigo are caused by S. aureus. 
Occasionally non-bullous impetigo can be caused by S. pyogenes. 
General predisposing factors for impetigo are a warm climate and high humidity. In Sweden, the 
incidence of impetigo peaks during the warmer months of the year (July-September). Predisposing 
factors for individuals are skin trauma and atopy.   
As revealed by its full name, the infection is highly contagious and minor epidemics often occur in 
day care centers and schools. Impetigo also spreads rapidly within households.  
Despite being consistently cited as a very common infection in medical textbooks and scientific 
publications (even the most common skin infection in children globally) incidence rates are hard to 
appreciate. The most exact incidence numbers probably come from a series of meticulous 
Norwegian studies of impetigo in an island community during the years 2001-2009. Incidence rates 
ranged from 0.0057 to 0.0260 cases per person-year in a well-defined population of 4500 people 
[74].   
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Diagnosis and management 
Typical skin lesions are usually present and the diagnosis impetigo is easily made. Even though S. 
aureus is almost always the causative agent a swab sample for bacterial culture should still be 
undertaken to rule out S. pyogenes and to obtain an antibiotic resistance profile for the S. aureus 
isolate at hand.  
 
The Swedish Medical Products Agency (Läkemedelsverket) regularly issues evidence-based 
recommendations for the treatment of impetigo and other bacterial SSTIs. The latest update was 
published in 2009 and the key points are summarized in the following [75]. Earlier this year (2012) 
an updated Cochrane review of interventions for impetigo was published and the result of that 
review is commented in relation to the Swedish guidelines [76].  
 
• Mild cases of impetigo are usually self-healing with the aid of a careful hygiene regimen to 
promote quicker recovery and prevent further spreading. Crust should be removed daily and 
the skin washed with water and a mild soap. Repeated use of unwashed towels should be 
avoided. Hands should be washed frequently and hand disinfectant used. The Swedish 
Medical Products Agency states that there is some evidence to suggest that application of 
chlorhexidine on lesions can be beneficial. The Cochrane review found lack of support for 
disinfection measures to manage impetigo.   
• Topical retapamulin applied twice daily for five days is recommended if symptoms persist 
despite the described hygiene regimen. Retapamulin was approved in the EU in 2007. It 
belongs to a new class of antibiotics, the pleuromutilins, and targets bacterial ribosomes in a 
novel way which it does not share with any other antibiotic [77]. To date, clinically relevant 
resistance to retapamulin or cross-resistance with other antibiotics has not been reported.  
• Topical fusidic acid is not recommended due to resistance among S. aureus isolates. 
Similarly, topical mupirocin is not recommended due to increasing reports of resistance 
outside of Sweden. At present, topical mupirocin is used exclusively in the attempt to 
eradicate MRSA from Swedish carriers and holds no place in the treatment of impetigo. The 
Cochrane review found that topical fusidic acid and topical mupirocin were equally or more 
effective than oral antibiotic treatment but remarked on the growing resistance rates for 
commonly used antibiotics.  
• Oral antibiotic treatment is recommended in widespread or progressing impetigo. The 
Cochrane review comments that there is a lack of studies in patients with extensive impetigo 
so it is unclear if oral antibiotics are superior to topical antibiotics in this group.  
• For children cefadroxil 25-30 mg/kg and day divided into two doses daily or flucloxacillin 
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50-75 mg/kg and day divided into three doses daily is recommended. Clindamycin 15 mg/kg 
and day divided into three doses is recommended in case of allergy to penicillin. Seven days 
of treatment is suggested for cefadroxil, flucloxacillin and clindamycin. 
• For adults flucloxacillin or dicloxacillin 750-1000 mg three times daily or cefadroxil 500-
1000 mg twice daily is recommended. Clindamycin 150-300 mg three times daily is 
recommended in case of allergy to penicillin. Seven days of treatment is suggested for 
flucloxacillin, dicloxacillin, cefadroxil and clindamycin. 
 
In paper II we have investigated and compared the bacterial spectrum in two mainly S. aureus-
associated skin diseases, impetigo and secondarily infected AD, with special emphasis on fusidic 
acid-resistant S. aureus (FRSA). 
 
 
ATOPIC DERMATITIS 
  
AD is a chronic or relapsing inflammatory skin disease characterized by dry skin, erythematous 
macules or plaques and pruritus. Up to 20% of children and 1-3% of adults, with some regional 
variations, are affected throughout the world [78]. Children of parents with AD have increased risk 
of developing AD and there is 80% concordance in monozygous twins and 20% in heterozygous 
twins, demonstrating a strong hereditary influence. AD is strongly associated with other 
manifestations of atopy (allergic rhinoconjunctivitis and asthma). 
 
The exact pathophysiology of AD is not known but alterations in immune reactivity, skin barrier 
function, allergens and microbial colonization are all considered important factors.  
 
AD patients have an immune deviation towards Th2 and increased IgE production. Elevation of 
total or allergen-specific IgE levels is one of the most typical laboratory biomarkers for AD. 
However, this is controversial since not all patients with AD have raised IgE levels, a fact which 
further complicates the understanding of the pathophysiology of the disease. The terms extrinsic 
(IgE-associated) and intrinsic (non-IgE-associated) AD have been coined to separate two clinically 
distinct groups of patients. Patients with intrinsic AD  do not have bronchial asthma or allergic 
rhinitis, show normal total serum IgE levels, no specific IgE, and negative skin-prick tests to 
aeroallergens or foods [79]. 
Genetic studies have not been able to detect candidate genes which are unique to AD but rather 
found genes which are also associated with other diseases of immune dysregulation such as asthma 
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and allergies. Examples of identified genes are Toll-like receptor 2 (TLR2), nucleotide-binding 
oligmerization domain I (NOD1) and CD14 (monocyte differentiation antigen), involved in antigen 
presentation and cell-mediated and humoral immune response pathways [80].  
 
The impaired skin barrier function of AD has received much attention in recent years after the 
discovery of loss-of-function mutations in the epidermal barrier protein filaggrin (FLG) as a 
predisposing factor for AD [81]. Filaggrin functions in the ordered formation of the cornified 
envelope, the outermost layer of the epidermis. It does so by aggregating the cytoskeleton of 
keratinocytes. In the process, filaggrin is proteolyzed into pyrrodiline carboxylic acid and trans-
urocanic acid that contribute to the composition of the water-binding so-called natural moisturizing 
factor (NMF) of the skin [82]. The consequence of FLG loss-of-function mutations is decreased 
stratum corneum hydration. The resulting impaired skin barrier is believed to, at least partly, explain 
an increased susceptibility to allergic sensitization, microbial colonization and infections in patients 
with AD. In addition to mutations in FLG, genomic profiling of mRNA in AD has detected defects 
in expression of several other genes encoding structural proteins of the cornified envelope [80]. 
The FLG mutations are not only associated with AD but also with asthma, but only in patients who 
suffer from AD [83-85]. This association together with the current knowledge of the impaired skin 
barrier and the altered immune response is considered to support the idea of a march towards atopy 
initiated in early life. The decrased hydration and the defective structure of the skin makes it 
permeable to allergens and microbes. The penetrating allergens and microbes are believed to trigger 
a dysfunctional immune response starting in the skin and disseminating, leading to the secondary 
development of allergies and asthma [80, 86].  
 
The role of microbes 
AD patients are characterized by a remarkably high cutaneous colonization rate with S. aureus, 
frequencies reaching 90% on lesional skin in some reports [87-91]. It is evident that atopic skin is a 
favourable habitat for S. aureus. In atopic skin, fibronectin is redistributed to the cornified layer and 
S. aureus possesses adhesins (fibronectin binding protein A and B) which bind fibronectin [19].  
Colonization with S. aureus is a predisposing factor for SSTIs. In accordance, flare-ups of AD are 
frequently associated with S. aureus superinfection and require oral antibiotic treatment in addition 
to intensified topical anti-inflammatory therapy [92]. 
While the impact of S. aureus in flared superinfected AD is undisputed the role of this diversified 
pathogen in clinically non-infected AD is less clear. The density of S. aureus cutaneous colonization 
in AD has been reported to correlate with disease severity [88, 93]. The presence of exotoxin- and 
superantigen toxin-producing strains of S. aureus on the skin has been associated with exacerbation 
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of AD [94, 95]. Decreasing inflammation in AD with topical corticosteroids, TCI or UV-therapy 
generally decreases disease severity as well as cutaneous S. aureus colonization [96-99].  
Taken together these data have led clinicians to assume that topical anti-inflammatory treatment in 
combination with staphylococcal reduction can improve AD management. This was supported by a 
2009 placebo-controlled study from the U. S. where recurring use of dilute bleach baths was 
combined with intermittent intranasal application of mupirocin ointment in children with moderate 
to severe AD. The combination treatment reduced AD severity compared to placebo [100]. In 
contrast, a previous British study in children in from 1998 showed no effect on disease severity in 
children with clinically non-infected AD receiving oral flucloxacillin for 4 weeks with an 8-week 
post-treatment follow-up [101]. 
A recent Cochrane review on the effect of anti-staphylococcal interventions in patients with 
clinically non-infected AD could not support the efficacy of such interventions. The authors stated 
that there was a lack of high-quality randomized controlled clinical trials and that better and longer-
term studies are needed to show clear evidence of clinical benefit [5]. It is also possible that there 
are different patterns of S. aureus carriage within the AD cohort and that this might affect the 
outcome of intervention studies. 
Candida and Malassezia species have been implicated as aggravating factors in subsets of AD 
patients but the association is not clear since studies show conflicting results [38]. While not 
causative agents of AD, Malassezia species may play a role for AD severity in adult patients with 
head and neck dermatitis who do not respond to conventional therapy [102, 103]. 
 
In paper IV we investigate the longitudinal variation of different aspects of S. aureus colonization in 
adults with AD and relate our findings to disease severity.  
 
Diagnosis and management 
The diagnosis AD is criterion-based and is usually readily made on the basis of clinical inspection 
and patient history. Hanifin and Rajka and The U.K. Working Party have established criteria for the 
diagnosis of AD [104, 105]. These criteria were used in paper IV. 
 
Hanifin and Rajka Diagnostic Criteria for AD 
  
Major criteria: Must have three or more of: 
1. Pruritus 
2. Typical morphology and distribution  
• Flexural lichenification or linearity in adults 
• Facial and extensor involvement in infants and children 
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3. Chronic or chronically-relapsing dermatitis 
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis) 
 
Minor criteria: Should have three or more of: 
1. Xerosis 
2. Ichthyosis, palmar hyperlinearity, or keratosis pilaris 
3. Immediate (type 1) skin-test reactivity 
4. Raised serum IgE 
5. Early age of onset 
6. Tendency toward cutaneous infections (especially S aureus and herpes simplex) or impaired 
cell-mediated immunity 
7. Tendency toward non-specific hand or foot dermatitis 
8. Nipple eczema 
9. Cheilitis 
10. Recurrent conjunctivitis 
11. Dennie-Morgan infraorbital fold 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor or facial erythema 
16. Pityriasis alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool and lipid solvents 
20. Perifollicular accentuation 
21. Food intolerance 
22. Course influenced by environmental or emotional factors 
23. White dermographism or delayed blanch 
 
 
There is no laboratory test pathognomonic for AD. Histopathology on a skin biopsy can support the 
diagnosis but does not give a definitive answer. 
The European Task Force on Atopic Dermatitis (EFTAD) has recently published guidelines for the 
treatment of AD [106, 107].  Selected key points from these guidelines are summarized in the 
following. A majority of AD patients manage their dermatitis satisfactorily with continuous use of 
topical emollients combined with intermittent use of topical corticosteroids or calcineurin inhibitors 
(TCI). 
 
• Topical emollients 
Topical emollients are the mainstay of maintenance therapy and rehydrate the skin. It is 
preferentially applied after a bath or a shower on slightly humid skin. Glycerol appears 
better tolerated than urea and propylene glycol, and is preferred in children. Emollients 
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should be used liberally and frequently. Quantities required are estimated to 150-200 g per 
week in young children and up to 500 g per week in adults. There is evidence to support that 
regular use of emollient (after an induction of remission with topical corticosteroids) has 
corticosteroid sparing effects in mild to moderate AD. 
 
• Avoidance of non-specific provocation factors and aeroallergens 
Mechanic irritants (wool) and chemical irritants (repeated occupational or household 
exposure to water, detergents and solvents) should be avoided. 
The value of avoidance of allergens is less clear. There is some evidence to suggest that 
house dust mites (Dermatophagoides pteronyssinus and D. farinae) provoke symptoms of 
AD and that special encasings on mattresses and pillows may be beneficial. 
 
• Food allergens 
Cow´s milk, hen´s egg, wheat, soy, tree nuts and peanuts can cause or exacerbate dermatitis 
during infancy [108]. There is little evidence to support effect of an elimination diet in 
unselected groups of patients with AD. The guidelines conclude that patients with moderate 
to severe AD should eliminate foods that provoked early or late reactions upon controlled 
provocation tests. 
 
• Topical anti-inflammatory therapy 
Topical corticosteroids and TCI have significant effect on skin lesions of AD compared to 
placebo. 
Topical corticosteroids should be used liberally during acute flares. Potency and formulation 
is chosen based on body site and intensity of symptoms. Application of topical anti-
inflammatory therapy should follow the finger-tip unit rule. 0.5 g of ointment is enough to 
cover two adult palm areas or 2% of an adult body surface. This amount is expressed from a 
tube with a 0.5 centimeter nozzle from the distal skin crease to the top of the index finger.  
After improvement, steroids are tapered to avoid withdrawal rebound. Proactive therapy 
with long-term twice weekly application may help to reduce relapses.  
TCI do not induce atrophy and can be an alternative to topical corticosteroids around the 
eyes, on the perioral skin and in skin folds. There is, to date, no scientific evidence of an 
increased risk of lymphoma, skin cancer or other malignancies due to TCI. Proactive 
therapy with twice weekly application of tacrolimus may help to reduce relapses. 
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• Antihistamines 
There is not enough evidence to support use of antihistamines in the treatment of pruritus in 
AD. 
• Phototherapy 
UVB+UVA (280-400 nm), broadband UVB (280-320 nm), narrow-band UVB (peak 311-
313 nm) and UVA1 (340-400 nm) can all improve the symptoms of AD. Effects of UV-light 
thought to be of importance in AD treatment is the modulation of the immune system 
through apoptosis of inflammatory cells, inhibition of Langerhans cells and alteration of 
cytokine production [109]. 
Narrow-band UVB is less erythemogenic and preferred to broad-band UVB. UVA1 is 
preferred in severe cases. 
 
• Systemic immunosuppressive treatment 
Oral glucocorticosteroids have an unfavourable risk/benefit ratio and long-term use is not 
recommended in the treatment of AD. Short-term use for acute flares in exceptionally severe 
cases could be considered. 
Ciclosporin may be used in chronic, severe cases of AD in adults. Azathioprine, 
mycophenolate mofetil or methotrexate may be used (off label) in adults AD patients if 
ciclosporin is ineffective or contraindicated. 
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ANTIBIOTICS AND ANTISEPTICS 
 
FUSIDIC ACID AND FUSIDIC ACID-RESISTANT S. AUREUS (FRSA) 
 
History of fusidic acid  
Fusidic acid is a narrow spectrum anti-staphylococcal antibiotic which was introduced by the 
Danish company Leo Pharma in 1962 [110]. It was isolated from the fermentation broth of the 
fungus Fusidium coccineum. Fusidic acid has a steroid-like structure and is the only member of the 
fusidane class of antibiotics (Figure 2). After oral administration it is readily absorbed, shows high 
and long-lasting serum levels and penetrates bone tissue, synovial fluid and heart tissue [111]. 
 
 
 
Figure 2. Structure of fusidic acid. 
 
 
In Europe, fusidic acid has been available as various topical preparations for the treatment of 
impetigo and other superficial staphylococcal skin infections [112]. In Australia, Canada, Europe 
and some parts of Asia systemic fusidic acid treatment has been used for difficult-to-treat S. aureus 
infections, i. e. osteomyelitis, joint graft infections and endocarditis [113-115].  
In Sweden, topical fusidic acid is available as a cream 2%, an ointment 2% and an ointment-soaked 
dressing 30 mg/dm2. For use in opthamology there is an ointment 2% for application in the 
conjunctival sac. For systemic use, sodium fusidate is available as a 250 mg tablet and as a 
formulation for infusion [116]. 
In vitro, fusidic acid has high activity against S. aureus, including MRSA, and S. epidermidis [117]. 
The fact that clinical MRSA isolates can be sensitive to fusidic acid is of great clinical importance. 
Systemic fusidic acid is generally used in combination with other antimicrobial agents, e.g. 
rifampicin, since in vitro exposure selects for resistance in S. aureus [118].  
Fusidic acid has never been approved in the U. S. but with the emerging epidemic of MRSA and 
34 
 
CA-MRSA voices from the pharmaceutical industry are being raised for the introduction of an oral 
preparation of fusidic acid [119]. 
 
Mechanism of action 
Fusidic acid is an inhibitor of bacterial protein synthesis through binding of the bacterial GTPase 
elongation factor G (EF-G) [111]. EF-G interacts with the ribosome during protein synthesis to 
catalyze translocation of the mRNA-tRNA complex which is needed for peptide chain enlongation 
in the translation of mRNA to protein [120]. When fusidic acid binds EF-G it prevents the EF-G-
ribosome interaction and stalls protein synthesis. This mechanism of translation inhibition is unique 
to fusidic acid. There is no known cross-resistance between fusidic acid and any other class of 
antibiotics. 
The main niche for fusidic acid in Europe has been topical preparations for the treatment of 
superficial S. aureus skin infections (impetigo, secondarily infected AD). Topical antibiotics are 
known to exert selective pressure and promote antibiotic resistance. Even though the preparations 
were widely used for more than three decades there were few reports of staphylococcal resistance to 
fusidic acid up until the late 1990s [121]. 
 
Fusidic acid-resistant S. aureus (FRSA) 
At the beginning of the new millennium, widespread outbreaks of bullous impetigo were noted in 
children in Sweden and Norway. It was discovered that these outbreaks were caused by the same 
fusidic acid-resistant S. aureus clone and the epidemiological data was published in 2002 [122, 
123].  In the years that followed there was increased surveillance of FRSA in Europe. The presence 
of the same FRSA clone was subsequently established in the U.K., Ireland and France [124-126]. In 
a recently published study based on data from 2007-2008 it also appears highly prevalent in the 
Netherlands [127].  
Fusidic acid-resistance in S. aureus isolates can arise through two principally different mechanisms. 
Mutation in fusA (the gene on the bacterial chromosome coding for EF-G) was the first identified 
cause of resistance. The altered EF-G does not bind fusidic acid as effectively and bacterial protein 
synthesis remains undisturbed [128]. Alternatively, S. aureus can harbour genes coding for proteins 
that protect EF-G from fusidic acid-binding. These genes (fusB, fusC and fusD) can be located on 
plasmids or the bacterial chromosome [129, 130]. It is currently not known which of the fusA-D 
determinants are the most prevalent in clinical FRSA isolates [131]. 
The impetigo-associated FRSA clone identified throughout Europe has been carefully characterized 
and named the epidemic European fusidic acid-resistant impetigo clone (EEFIC) [112, 132]. MIC 
for fusidic acid against the EEFIC has been shown to be approximately 4 mg/L [112]. 
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The EEFIC carries the fusB determinant on its chromosome. It is further characterized by agr allelic 
group IV, spa type 171 and the presence of exfoliative toxin etA and often etB [112, 125]. The 
EEFIC is strongly associated with bullous impetigo. 
Unsurprisingly, there seems to be an association between the patterns of prescription and use of 
fusidic acid and FRSA levels [133]. The emergence of the FRSA clone in Sweden and Norway 
coincided with increased prescription of topical fusidic acid products. Specifically, in 2001 a sales 
peak for topical fusidic acid was reached in eight Swedish counties followed by a peak in FRSA-
levels in 2002. During the following two years topical fusidic acid sales and FRSA levels declined 
[134]. A contrasting report from the U.K. demonstrated persisting high levels of FRSA despite a 
drop in topical fusidic acid use. There was even an increase in FRSA levels in non-dermatology 
outpatients and hospital patients. The authors suggested that a reservoir of FRSA had been attained 
in the community and that longer follow-up was needed to witness any effects of restricted use of 
topical fusidic acid [135]. Recent use, prolonged use and intermittent use of topical fusidic acid 
have been described to influence FRSA rates in dermatology outpatients with AD [136, 137].  
The emergence of the FRSA prompted the Swedish Medical Products Agency (Läkemedelsverket) 
to revise their guidelines on the treatment of impetigo in 2003. Avoidance of topical fusidic acid 
was recommended and this recommendation remained in the 2009 revision [75, 138]. Several 
authors outside of Sweden also advised on restrictive use of topical fusidic acid preparations [118, 
139, 140].  
While different aspects of FRSA and impetigo have been generously studied there are relatively few 
publications focusing on the prevalence of FRSA in AD. Since topical fusidic acid is used primarily 
in Europe most studies originate there. A dermatology inpatient department in the Netherlands 
reported increasing rates of FRSA in patients with AD, ranging from 9.7% in the mid-90s to 23.4% 
in 2001 [141]. An outpatient clinic in Cambridge reported FRSA in 50% of AD patients tested in 
2002 [136]. One German study published in 2004 discovered 6% fusidic acid-resistance in S. 
aureus isolates from children with AD while another German study published in 2008 found FRSA 
in 25% of S. aureus-positive skin swabs from children and adults with AD [142, 143]. The highly 
variable reports are likely due to regional differences in the use of topical fusidic acid and to the fact 
that the investigations were conducted at different time points in the European FRSA epidemic. 
 
ResNet, a Swedish antimicrobial resistance-surveillance database, offers monitoring of FRSA levels 
for each county and the whole nation [144]. The data provided by ResNet is based on antibiotic 
resistance profiles for 100 consecutive strains of S. aureus sent in by all county laboratories once 
yearly. Fusidic acid-resistance is consistently the most prevalent antibiotic resistance in S. aureus 
(susceptibility to erythromycin, clindamycin, gentamycin, norfloxacin, fusidic acid and cefoxitin 
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(screen for MRSA) is tested). FRSA levels peaked at 9.6% in 2002, declined to 3.8% in 2005 and 
were then stabilized at 4.0-6.0% in the years that followed. In 2011, FRSA levels were 6.0%.  
During the same time period (2002-2011) MRSA levels have gradually increased from virtually 
non-existent to 1.2% in 2011. 
 
In paper II we have investigated the rate of FRSA in bullous impetigo, non-bullous impetigo and 
secondarily infected AD in patients attending a major dermatology clinic in the second-largest city 
in Sweden in the years 2004-2008. 
 
 
ANTISEPTICS 
 
Biocides are broad-spectrum chemical agents that inactivate microbes [145]. Biocides can be “-
static” (bacteriostatic, fungistatic, sporistatic) which means they inhibit growth of microbes or “-
cidal” (bactericidal, fungicidal, sporicidal) which means they kill microbes. Biocides used on living 
tissue are referred to as antiseptics whereas those used on surfaces and inanimate objects are 
referred to as disinfectants. While antibiotics inhibit specific metabolic pathways or the processing 
of the bacterial genome, usually at low concentrations, antiseptics have a less specific (and in most 
cases only partly defined) mode of action. Clinically significant antimicrobial resistance against 
antiseptics is much less common than resistance against antibiotics. This is probably due to the 
broader range of activity of antiseptics, often on multiple cellular targets. However, both innate and 
acquired antimicrobial resistance against antiseptics does exist. There is increasing concern that the 
use of biocides in health care, consumer prodcucts and in industrial settings contributes to the 
development and selection of antibiotic-resistant strains [146]. Acquired antimicrobial resistance 
against antiseptics has been described for S. aureus [145]. Antiseptics can also cause contact 
dermatitis and even anaphylactic reactions [147]. 
 
Alcohols  
Alcohol formulations are commonly used for hand surface disinfecting, e. g. by health care workers. 
Alcohols have the ability to damage cell membranes and denature proteins of microbes. They are 
effective against vegetative bacteria, viruses and fungi but are not sporicidal [145]. 
 
Chlorhexidine 
Chlorhexidine is a bactericidal agent. It damages and penetrates the cell wall and cell membrane, 
presumably by passive diffusion, causing leakage and coagulation of the cytoplasm [145]. 
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Cutaneous exposure to chlorhexidine can cause anaphylactic reactions [148, 149]. It has also been 
suggested that the low prevalence of delayed hypersensitivity to chlorhexidine is underestimated 
[147]. 
 
Hydrogen peroxide 
Hydrogen peroxide acts as a powerful oxidant. It produces the hydroxyl radikal ˙OH which oxidizes 
cell components such as lipids, proteins and DNA. It has been suggested that exposed sulfhydryl 
groups and double bindings are especially vulnerable. Hydrogen peroxide is effective against 
bacteria, bacterial spores, fungi and viruses [145]. Gram-positive bacteria are more susceptible than 
gram-negatives. If a microbe produces catalase or other peroxidases this may serve as partial 
protection. Catalase promotes 2H2O2 → 2H2O + O2, thus limiting hydroxyl radical formation. There 
are no known microbes that are resistant to hydrogen peroxide. 
  
Microcid®, a hydrogen peroxide cream introduced in 1994 for the treatment of impetigo, was tested 
in a double-blind randomized multi-centre trial against topical fusidic acid and was found to be 
equally effective [150]. It was included in the 2003 Swedish Medical Product Agency guidelines for 
impetigo treatment as an optional complement to the recommended hygiene measures [138]. 
However, Microcid® did not prove to be as clinically effective as anticipated.  In the current 
guidelines it is not included [75]. 
 
Clioquinol 
Clioquinol (5-chloro-7-iodo-8-quinolinol) belongs to the chinoline colours and has been used as a 
drug since the 1950s. Initially, an oral formulation was prescribed for the treatment of intestinal 
amoebas. However, several reports of neurotoxicity in Japanese patients in the 1970s led to the 
withdrawal of clioquinol. Recently, clioquinol has received new attention due to its ability to 
dissolve copper from beta amyloid protein aggregates associated with Alzheimer´s disease. It is also 
known that clioquinol can induce cell death in malignant cells. It does so by inhibiting the 
proteasome, the “waste basket” organelle which is comprised of protelytic enzymes and degrades 
ubiquinated proteins destined for destruction [151]. The mechanism behind the antimicrobial effect 
of clioquinol is not known [152]. Clioquinol is used as a topical antiseptic in dermatology. Its origin 
from the group of chinoline colours is evident from the temporary yellowish discolouration of the 
skin which is created upon use. In Sweden, clioquinol is available as an additive (3%) to 
betamethasone cream or ointment. There are few reports of resistance against clioquinol. It is not a 
common contact allergen and has not been associated with skin malignancies [151]. Treatment 
periods should be kept short and use is not advised in young children [153]. 
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Halquinol, a related substance, has previously been available in Sweden, as an additive (0.75%) to 
triamcinolone cream. It was discontinued for unknown reasons during the progress of this work but 
is featured in paper III together with clioquinol and a hydrogen peroxide formulation. 
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AIMS OF THE STUDIES 
 
PAPER I 
 
To describe the frequency and distribution of bacteria and the yeasts Candida and Malassezia in 
balanoposthitis.  
To investigate if different microbes correspond to distinct clinical presentations of balanoposthitis. 
To investigate a possible association between Malassezia and balanoposthitis. 
To investigate a possible association between balanoposthitis and seborrhoeic dermatitis or 
psoriasis.  
 
PAPER II 
 
To investigate the bacterial spectrum in patients with impetigo, bullous impetigo and secondarily 
infected AD. 
To investigate the prevalence of fusidic acid-resistance among S. aureus isolates from patients with 
non-bullous impetigo, bullous impetigo and secondarily infected AD. 
 
PAPER III 
 
To test the in vitro antimicrobial activity, expressed as MIC against selected microbes, of commonly 
used topical skin pharmaceuticals and their active substances. 
 
PAPER IV 
 
To describe variations in S. aureus colonization (body sites, density, strain identity) and relate these 
variations to disease severity, expressed as SCORAD, during a 5-month follow-up of adult patients 
with AD. 
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MATERIAL AND METHODS 
 
SUBJECTS AND SAMPLES 
 
PAPER I 
The study was performed in the venereology clinic of the Department of Dermatology and 
Venereology at Sahlgrenska University Hospital, where we see patients with STIs and genital 
dermatoses. A total of 102 patients presenting with balanoposthitis between 2004 and 2006 were 
included in the study. Twenty-six patients with no clinical signs or medical history of 
balanoposthitis served as a control group. 
 
 Balanoposthitis group 
n = 102* 
Control group 
n = 26 
Balanoposthitis 102 - 
Bacterial STIs   
Chlamydia trachomatis urethritis 3 2 
Mycoplasma genitalium urethritis - 1 
Viral STIs   
Herpes simplex type 2 1 - 
Varicella zoster (right leg) - 1 
Condylomata acuminata 2 8 
Molluscum contagiosum 1 2 
Other   
Eczema nummularis (extragenital) 1 - 
Folliculitis 1 1 
Non-malignant preputial epithelial  
hyperplasia 
1 - 
Non-specific urethritis 5 2 
Pruritus scrotalis - 1 
STI check-up - 8 
Zoon balanitis 1 - 
 
Table I. Additional diagnoses in the balanoposthitis group and reasons for the visit in the control 
group 
*The total number of diagnoses in this column exceeds the number of patients, since some patients 
received diagnoses in addition to balanoposthitis. STI: sexually transmitted infection. 
Modified from Alsterholm et al [154] (= paper I) with permission from the publisher. 
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Some patients with balanoposthitis had additional diagnoses. A majority of patients in the control 
group attended the clinic for routine STI check-up or genital warts (Table I). It is important to note 
that genital warts or other dermatoses in the control group did not affect the area of the prepuce or 
glans penis. 
It can be argued that peri-genital dermatoses such as genital warts could influence frequency and 
distribution of microbes on the prepuce and glans penis indirectly. To avoid this possible bias, an 
alternative way to recruit a control group could have been to choose age-matched patients attending 
the dermatology section of our clinic or to advertise for healthy volunteers. However, we could not 
assume that general health and lifestyle factors would be similarly distributed in such a group. In 
addition, we had ethical considerations regarding recruitment of a control group outside the 
venereology section. Inspection and swabs of the genital area are not regarded as a routine 
examination by most patients. It could prove difficult to find volunteers willing to participate. 
 
Ages in the balanoposthitis group ranged from 19 to 71 years (median 28, mean 33 years). Ages in 
the control group ranged from 18 to 44 years (median 29, mean 29 years). Two patients in the 
balanoposthitis group and one patient in the control group were circumcised.  
 
Presence or absence of predetermined clinical criteria for balanoposthitis was assessed in each 
patient. The criteria for the diagnosis balanoposthitis was presence of one or more of the following; 
erythema, papules, pustules, transudate, white membranes or fissures in the area of the prepuce and 
glans penis. All patients underwent clinical examination of the skin including the scalp to assess 
presence or absence of seborrhoeic dermatitis or psoriasis.  They were also asked if they had 
previously experienced symptoms of seborrhoeic dermatitis or psoriasis. Swab samples from the 
area of the prepuce and glans penis for bacterial culture, Malassezia culture and semiquantitative 
Candida culture was secured from all patients. 
 
 
PAPER II 
 
A prospective study of the bacterial spectrum and prevalence of fusidic acid-resistance among S. 
areus isolates in patients with impetigo and secondarily infected AD was conducted in the time 
period 2004-2008. In addition a patient record review was made covering the first (2004-2005) and 
last (2007-2008) years of the prospective study.  
At the time of the study, the Department of Dermatology ran clinics in the three hospitals serving 
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the greater Gothenburg area (Sahlgrenska Hospital, Östra Hospital and Mölndal Hospital). Impetigo 
and secondarily infected AD are considered emergency dermatology cases and are usually, but not 
exclusively, referred to our on-call dermatologist who works in the largest clinic located at 
Sahlgrenska Hospital. The authors of paper II recruited patients for the prospective study when they, 
on a regular basis, served as the on-call dermatologist. This arrangement explains why the number 
of patients included in the prospective study is low in relation to the total number of patients 
presenting with impetigo or secondarily infected AD at the Department of Dermatology. Also, the 
patients were not strictly consecutive since the reality of clinical work does not always allow time 
for the inclusion in a study.  
The intermittent recruitment was considered a weakness of the study that could result in an 
involuntarily biased selection of patients. Therefore, we performed a patient record review. The 
review was aimed at finding all cases of impetigo and secondarily infected AD at the Department of 
Dermatology and collect bacterial culture data when available.  
 
In the following, the prospective study 2004-2008 and the patient record review are described 
separately. 
 
Prospective study 2004 to 2008 
The study was performed at the Department of Dermatology and Venereology at Sahlgrenska 
University Hospital, Gothenburg, Sweden, from June 2004 to May 2008. Patients who presented to 
the authors at Sahlgrenska Hospital with either impetigo, bullous impetigo or secondarily infected 
AD were asked to participate. There was no selection based on gender or age, nor were patients 
selected to be seen by the authors. All patients consulting with the Department of Dermatology need 
a referral which is usually issued by a general practitioner at a primary health care facility. Skin 
lesions were examined and the diagnosis impetigo, bullous impetigo or secondarily infected AD 
was made based on clinical evaluation. A swab sample for bacterial culture was secured from a 
clinically infected skin lesion in each patient. Bacterial cultures were sent to the Department of 
Clinical Bacteriology, Sahlgrenska University Hospital, according to standard procedure.  All S. 
aureus isolates from clincal samples are routinely tested against fusidic acid, cefoxitin (screening 
for MRSA), clindamycin, erythromycin and tobramycin. 
Seventy-five patients, 38 presenting with impetigo (13 of whom had bullous impetigo) and 37 with 
secondarily infected AD, agreed to participate in the study. The age range in the impetigo group was 
1–49 years, with a mean of 18 years and a median of 17 years. The age range in the bullous 
impetigo group was 2–30 years (mean 18 years, median 18 years). The age range in the secondarily 
infected AD group was 6 months to 62 years (mean 30 years, median 29 years). 
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Patient record review  
The patient record review covered all patients attending the three clinics of the Department of 
Dermatology for impetigo or secondarily infected AD. All patient records at the Department of 
Dermatology are computerized. The review was carried out in 2009.  
 
A search for all patients receiving the diagnostic codes for “Impetigo” (L01.0 and L01.0X), 
“Secondarily infected dermatoses” (L01.1), “Prurigo Besnier” (L20.0), “Otherwise specified AD” 
(L20.8) or “AD unspecified (L20.9)” in the time periods June 2004 to May 2005 and June 2007 to 
May 2008 was made. The diagnostic codes which are used come from the Swedish version of the 
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision 
(ICD-10). One or more diagnostic codes are routinely assigned to every patient visit by the 
dermatologist who was consulted. In the patient record review, impetigo could not be differentiated 
into the non-bullous and bullous types with certainty because the description of the clinical 
presentation was sometimes limited. 
 
The search rendered a total of 2353 patient records (1184 from June 2004 to May 2005 and 1169 
from June 2007 to May 2008).  These patient records were reviewed by author MA.  
A total of 283 out of the 2353 records described dermatoses other than impetigo or AD or lacked a 
definitive diagnosis and were excluded. All records describing ongoing impetigo or secondarily 
infected AD together with the securing of a bacterial culture from afflicted skin were selected for 
further analysis. These records also included those of the patients who were included in the first and 
last year of the prospective study. The results of the bacterial cultures including antibiotic resistance 
patterns for S. aureus were collected from the register at the Department of Clinical Bacteriology.  
An overview of the patient record review is provided (Figure 3).  
In June 2004 to May 2005 there were 66 cases of impetigo and 55 cases of secondarily infected AD 
where a swab sample for bacterial culture was secured. The age range in the impetigo group was 9 
days to 81 years (mean 26 years, median 23 years). The age range in the secondarily infected AD 
group was 7 months to 86 years (mean 25 years, median 21 years). 
In June 2007 to May 2008 there were 53 cases of impetigo and 55 cases of secondarily infected AD 
where a swab sample for bacterial culture was secured. The age range in the impetigo group was 1–
90 years (mean 31 years, median 21 years). The age range in the secondarily infected AD group was 
1–90 years (mean 29 years, median of 24 years). 
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Figure 3. Patient record review 
 
A search for diagnostic codes L01.0 + L01.0X (Impetigo), L01.1 (Secondarily infected 
dermatoses), L20.0 (Prurigo Besnier), L20.8 (Otherwise specified AD) and L20.9 (AD unspecified) 
was made and retrieved records reviewed. Number of patients at each step in brackets. 
June 2004-May 2005 
Impetigo, Secondarily 
infected dermatoses (176) 
Prurigo Besnier, Otherwise specified 
AD, AD unspecified (1008) 
Impetigo 
(101) 
Other 
diagnoses 
(75) 
Bacterial 
culture (66) 
(66) 
No bacterial 
culture (35) 
(35) 
Atopic  
dermatitis 
(966) 
Other  
diagnoses 
(42) 
Flare-up 
(450) 
Non-flaring AD 
(516) 
Oral antibiotics  
prescribed 
(144) 
No oral antibiotics  
prescribed 
(306) 
 
Bacterial 
culture (55) 
(55) 
No bacterial 
culture (395) 
(395) 
June 2007-May 2008 
Impetigo, Secondarily 
infected dermatoses (104) 
 
Prurigo Besnier, Otherwise specified 
AD, AD unspecified (1065) 
 
Impetigo 
(53) 
Other 
diagnoses 
(51) 
Bacterial 
culture (33) 
(33) 
No bacterial 
culture (20) 
(20) 
Atopic  
dermatitis 
(950) 
Other  
diagnoses 
(115) 
Flare-up 
(545) 
Non-flaring AD 
(405) 
Oral antibiotics  
prescribed 
(124) 
No oral antibiotics  
prescribed 
(421) 
 
Bacterial 
culture (55) 
(55) 
No bacterial 
culture (490) 
(490) 
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PAPER III 
 
The MIC for topical skin pharmaceuticals and active substances from these pharmaceuticals were 
determined against selected microbes with agar dilution assay.  
 
Topical skin pharmaceuticals 
The following topical skin pharmaceuticals were tested. The formulations of the pharmaceuticals 
were all creams.  
 
Antibiotic formulation 
Fucidin® 2% (fusidic acid) (Leo Pharma, Malmö, Sweden)  
 
Antifungal formulations 
Canesten® 1% (clotrimazole) (Bayer, Solna, Sweden) 
Daktar® 2% (miconazole) (Janssen-Cilag, Sollentuna, Sweden) 
Lamisil® 1% (terbinafine) (Novartis, Täby, Sweden) 
 
Antifungal formulation with corticosteroid 
Daktacort® (miconazole 20 mg/g + hydrocortisone 10 mg/g) (Janssen-Cilag, Sollentuna, Sweden).  
 
Antiseptic formulation 
Microcid® 1% (hydrogen peroxide) (Bioglan Pharma, Malmö, Sweden) 
 
Corticosteroid formulation 
Betnovat® (betamethasone) (GlaxoSmithKline, Solna, Sweden) 
Emovat® 0.05% (clobetasone butyrate) (GlaxoSmithKline, Solna, Sweden) 
Dermovat® 0.05% (clobetasol) (GlaxoSmithKline, Solna, Sweden) 
Hydrokortison CCS® 1% (hydrocortisone) (Clear Chemical Sweden, Borlänge, Sweden)  
 
Corticosteroid formulations with antiseptic agent  
Betnovat® with chinoform (betamethasone 1 mg/g + clioquinol 30 mg/g) (GlaxoSmithKline, Solna, 
Sweden) 
Kenacutan® (triamcinolone 1 mg/g + halquinol 7.5 mg/g) (Bristol-Myers Squibb, Bromma, 
Sweden).  
Note: Clioquinol is 5-chloro-7-iodo-8-quinolinol and halquinol is a mixture of 5,7-dichloro-, 5-
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chloro- and 7-chloro-8-quinolinols. 
 
Active substances 
The following active substances were tested. 
 
Clioquinol (5-chloro-7-iodo-8-quinolinol) (Sigma-Aldrich, Stockholm, Sweden) 
Econazole nitrate salt (Sigma-Aldrich, Stockholm, Sweden) 
Fusidic acid (Sigma-Aldrich, Stockholm, Sweden) 
Ketoconazole nitrate salt (Sigma-Aldrich, Stockholm, Sweden)  
Miconazole nitrate salt (Sigma-Aldrich, Stockholm, Sweden) 
Terbinafine hydrochloride (Biomol, Immunkemi F & D, Järfälla, Sweden) 
 
Selected microbes 
The bacteria and yeast were reference strains obtained from Culture Collection University of 
Göteborg (CCUG); Candida albicans (CCUG 5594), Escherichia coli (CCUG 24), Staphylococcus 
aureus (CCUG 17621), Staphylococcus epidermidis (CCUG 39508) and Streptococcus pyogenes 
(CCUG 4207). 
 
Comments on the selection of pharmaceuticals, substances and microbes 
We wanted to explore antibacterial effects of antifungals and chose several antifungal formulations. 
For the antiseptics we wanted to test the species-related range of activity. In the case of the 
corticosteroids we wanted to investigate potential antimicrobial effects of additives and 
preservatives since the amount of S. aureus on atopic skin is reported to diminish after application 
of corticosteroids alone and the reason for this is not fully elucidated [96]. The topical antibiotic 
was chosen as a reference for anti-staphylococcal activity.  
Selected active substances from the formulations were tested alone to determine if other 
components of the formulations influenced antimicrobial activity. 
S. aureus was chosen because it is a frequent skin pathogen as well as a commensal. S. epidermidis 
was selected for being the most common coccus on human skin and a representative of the CoNS. 
S. pyogenes is a common pathogen associated with SSTIs and a member of the genus 
Streptococcus. E. coli represented the gram-negatives and was included since it can be a relevant 
colonizer of inflamed skin or even a primary pathogen. C. albicans was added as a reference since 
we tested antifungal preparations.   
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PAPER IV 
 
Variations in S. aureus colonization and disease severity in adult patients with AD were registered 
during a 5-month follow-up. 
The study was performed at the Department of Dermatology and Venereology and the Department 
of Microbiology at Sahlgrenska University Hospital in 2010-2012. A search of all patient records 
made during the period January 1 to September 22 2010 at the Department of Dermatology was 
conducted.  Search critera were patients 18 years or older who had received the diagnostic code 
“Prurigo Besnier (atopic dermatitis) L20.0” according to the Swedish version of the International 
Statistical Classification of Diseases and Related Health Problemn, Tenth Revision (ICD-10). 489 
patient records matched these criteria and were reviewed by author MA.  All patients with moderate 
to severe AD without ongoing systemic treatment (oral corticosteroids, other immunomodulators) or 
phototherapy were considered eligible for the study (n = 78). These patients were contacted by 
phone in random order and offered participation. Inclusion was stopped when 20 patients had 
agreed to participate. 
Eleven men and ten women agreed to participate in the study. Of those, eleven men and nine 
women completed follow-up. Age distribution was; all patients age range 26-66 years (mean 48 
years, median of 41 years); male patients age range 28-66 years (mean 41 years, median of 39 
years); female patients age range 26-65 years (mean 44 years, median 42 years). 
Follow-up for each patient was 5-6 months during which evaluation was made at three time-points 
(visit 1 at starting point, visit 2 after 2-3 months and visit 3 after 5-6 months). Follow-up took place 
between January 2011 and June 2011 with the exception of two patients who were followed-up 
from March 2011 to September 2011. The same protocol was used at each visit. A history of the 
patient´s treatment for AD during the last 2-3 months was taken, SCORAD assessment was 
performed by author MA and swab samples for qualitative and quantitative bacterial cultures were 
collected by authors MA and LS.  
 
SCORAD evaluation 
The severity of AD was assessed with the SCORAD index (severity SCORing of Atopic 
Dermatitis) [155]. The SCORAD index includes estimation of the body surface area affected by AD 
and grading of six intensity items (erythema, oedema/papulation, oozing/crusts, excoriations, 
lichenification and dryness). The combination of the area estimation and intensity grading renders a 
score which is referred to as objective SCORAD index (range 0-83). The SCORAD index also 
includes two subjective items. Patients are asked to grade their average pruritus and sleep loss, 
respectively, during the last three days and nights, by using a visual analogue scale. This grading 
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renders an additional score which is added to the objective SCORAD score. The total score is 
referred to as the total SCORAD index (range 0-103). Objective SCORAD index as well as total 
SCORAD index was calculated at all visits. The intra-individual and inter-individual relations 
between SCORAD indices were similar for objective SCORAD index and total SCORAD index. 
Statistical analysis was performed with both the objective SCORAD index and the total SCORAD 
index with similar results (data not shown).  
Due to current convention and to facilitate comparison with other studies, we chose to consistently 
use the objective SCORAD index in tables and figures. The intensity of AD was defined as mild 
(objective SCORAD index 0-15), moderate (objective SCORAD index 15-40) or severe (objective 
SCORAD index >40) according to the classification of Oranje et al [156].  
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LABORATORY METHODS 
 
PAPER I  
 
Culture and differentiation of bacteria and Candida species 
One cotton swab sample for bacterial culture and one for semi-quantitative Candida culture were 
obtained from the area of the prepuce and glans penis. Bacterial cultures were sent to the 
Department of Clinical Bacteriology according to standard procedure. Candida and Malassezia 
species were cultured and differentiated at the research laboratory of the Department of 
Dermatology which also serves as a clinical laboratory for the detection of cutaneous yeast and 
dermatophyte infections.  
Candida species were cultured on Sabouraud’s agar at 32ºC and growth visually quantified as very 
discrete, discrete, moderate or heavy. The isolates were then differentiated on CHROMagar™ 
Candida Medium plates (Becton Dickinson GmbH, Heidelberg, Germany). Colonies of C. albicans 
have a distinct green colour on CHROMagar medium, setting them apart from other Candida 
species [157, 158].  
 
Culture and differention of Malassezia species 
Samples for Malassezia cultures were obtained using a contact plate with Leeming-Notman agar 
pressed against the prepuce and glans penis. Leeming-Notman agar is the most effective culture 
media for isolation of Malassezia yeasts [159]. Semi-quantitative cultures for Malassezia species 
were made on the contact plates used for sampling followed by differentiation of the isolates. At the 
time of the study seven Malassezia species had been characterized in humans; M. furfur, M. 
pachydermatis, M. sympodialis, M. globosa, M. obtusa, M. restricta and M. slooffiae. 
The contact plates were incubated at 32 ºC for 7-14 days. Colonies were then counted and growth 
was quantified as > 5 colonies, 2–5 colonies or 1 colony. Morphologically different colonies were 
re-cultured on separate Leeming-Notman plates for further differentiation.  
Malassezia species grow selectively on media, are sensitive to temperature and exhibit different 
enzymatic activities. These properties are used to distinguish species according to the combined 
methods of Guillot et al and Mayser et al [38, 41, 42].  
Specifically, the isolates were cultured on Sabouraud dextrose agar at 32ºC and modified Dixon 
agar at 38ºC. Further differentiation was based on the catalase reaction determined by application of 
hydrogen peroxide, culture with Cremophor EL and β-glucosidase activity assayed by using esculin 
agar tubes. M. pachydermatis alone grows on Sabouraud´s agar. Several Malassezia species, but not 
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M. restricta, express catalase and split hydrogen peroxide into water and oxygen. M. furfur is the 
only species that can metabolize Cremophor EL (PEG-35 castor oil) and grows right up to the edge 
of a well containing Cremophor EL made on a Leeming-Notman plate. M. obtusa and M. 
sympodialis, but not M. globosa and M. slooffiae, split esculin in agartubes into esculetin and 
glucose turning the media black due to release of iron salts. M. sympodialis and M. slooffiae grow 
on Dixon agar at 38° C whereas M. globosa and M. obtusa do not. The combined growth/activity 
profile from the described tests determines the Malassezia species (Figure 4). 
 
 
PAPER II 
 
Cultures for bacteria and determination of fusidic acid-resistance in S. aureus isolates 
A swab sample for bacterial culture was taken from a clinically infected skin lesion in each patient.   
Specifically, isolates of S. aureus were visually detected on selective plates and verified by the 
coagulase test. All isolates of S. aureus were routinely tested for antibiotic resistance against 
cefoxitin, fusidic acid, clindamycin, erythromycin and tobramycin by disk diffusion on Mueller-
Hinton agar.  The S. aureus isolates were characterized as FRSA or fusidic acid-sensitive according 
to the breakpoints defined by EUCAST [160]. Disc content of fusidic acid was 10µg. Clinical 
breakpoint was a zone diameter of 24 mm corresponding to a MIC breakpoint of 1 mg/L (S ≤ 1 
mg/L, R > 1 mg/L).  
The full genetic characterization of the FRSA clonotype later named the EEFIC was not completed 
when this study started [112, 132]. Consequently, the FRSA isolates were not molecularly typed to 
determine if they belonged to the EEFIC.  
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Malassezia spp. 
 
Sab. 32 °C   Catalase Cremophor 
EL 
Esculin Dixon 38 ºC 
M. pachydermatis + +/- +/- +/- + 
M. furfur - + + - + 
M. sympodialis - + - + + 
M. slooffiae - + - - + 
M. obtusa - + - + - 
M. globosa - + - - - 
M. restricta - - - - - 
 
Figure 4. Differentiation of Malassezia species. 
All Malassezia isolates were cultured on Sabouraud agar (Sab.), modified Dixon agar (Dixon) and 
with Cremophor EL. Catalase activity was assayed by application of hydrogen peroxide (Catalase 
reaction). β-glucosidase activity was assayed by using esculin agar tubes (Esculin). + denotes 
growth or activity, - denotes abscence of growth or activity. The growth/activity profile determined 
the Malassezia species. 
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PAPER III 
 
Determination of MIC with agar dilution assay 
The MIC is the lowest concentration of a substance that will inhibit visible growth of a microbe 
after overnight incubation (this period can be extended for some slow-growing microorganisms). 
MIC is considered the golden standard for antimicrobial susceptibility testing and can be 
determined by agar or broth dilution assays [161, 162].  
It is possible to dissolve creams in agar and we chose this unconventional approach to determine the 
MIC of entire formulations against selected microbes. The colour and turbidity of the agar is 
affected when high concentrations of cream are dissolved but bacterial and yeast colonies are still 
easily recognizable on the plates. 
 
When using the agar dilution assay the substance that is being tested is dissolved in agar on plates in 
a range of concentrations (doubling dilutions steps up and down from 1 mg/L as appropriate). An 
inoculum of the microbe is applied on the plates and allowed to absorb. After overnight incubation, 
the plate with the lowest concentration of the substance that inhibits microbial growth is noted and 
represents the MIC of the substance against the microbe (Figure 5). 
 
 
 
Figure 5. Basic concept of MIC determination by agar dilution assay. 
 
 
The agar dilution assay was used to determine MIC for topical skin pharmaceuticals (below referred 
to as formulations) and active substances from these pharmaceuticals against S. aureus, S. 
epidermidis, S. pyogenes, E. coli and C. albicans.  
Dilution series for each formulation/substance were prepared in blood agar medium (Columbia agar 
(Oxoid, Basingstoke, U.K.) + 5% defibrinated horse blood) for S. pyogenes and in Diagnostic 
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Sensitivity Test (DST) agar (Oxoid) for S. aureus, S. epidermidis, C. albicans and E. coli. All 
dilution series were made with freshly prepared and autoclaved agar. The agar was allowed to cool 
to a temperature of 48–50°C in an incubator before a formulation or substance was added. 
Formulations were weighed and dissolved directly in agar for the concentrations 20% (10 g cream 
in a final volume of 50 ml agar, weight/volume (w/v)), 10% (w/v), 5% (w/v) and 1% (w/v). For the 
lower concentrations a stock solution of 1% (0.5 g cream in a final volume of 50 ml agar) was 
prepared and further diluted with agar to obtain concentrations 0.5–0.0001% (w/v). A pre-warmed 
oven with a constant temperature of 50°C kept the stock solution at an appropriate temperature 
during experimental procedures. Final concentration ranges were; Betnovat® 1–20% (w/v), 
Betnovat® with chinoform 0.005–20% (w/v), Emovat® 1–20% (w/v), Dermovat® 1–20% (w/v), 
Canesten® 1% 0.001–20% (w/v), Daktar® 2% 0.001–5% (w/v), Daktacort® 0.001–20% (w/v), 
Fucidin® 2% 0.0001%–20% (w/v), Hydrokortison CCS® 1% 1–20% (w/v), Kenacutan® 0.005–20% 
(w/v), Lamisil® 1% 0.001–20% (w/v) and Microcid® 1% 0.001–20% (w/v). Substances were 
dissolved in dimethylformamide (DMF) to prepare a stock solution of 10 mg/ml and this solution 
was further diluted and mixed with agar. When testing S. pyogenes, the stock solution was instead 
prepared with ethanol 99.5% (Kemetyl AB, Haninge, Sweden) because DMF was no longer 
recommended for laboratory use. Final concentration ranges were: clioquinol 0.125–100 µg/ml, 
econazole nitrate salt 1.0–50 µg/ml, fusidic acid 0.03125–25 µg/ml, ketoconazole 0.125–100 µg/ml, 
miconazole nitrate salt 0.125–100 µg/ml and terbinafine hydrochloride 0.5–50 µg/ml. The MICs 
against all microbes for DMF (range tested 0.625–10% (volume/volume = v/v)) or ethanol (range 
tested 0.625–10% (v/v)) were also determined to ensure that antimicrobial effect could not be 
attributed to the solvent for the active substances.  
Standard Petri dishes (92 × 16 mm (diameter × height)) were used and the agar volume in each plate 
was 25 ml. After the agar was poured, plates were allowed to cool and were then used immediately. 
There were duplicate plates for all dilution steps.  
Bacterial colonies from blood agar plates were used for preparation of the inoculums. C. albicans 
was grown on Sabauroud’s agar medium. Colonies were suspended in PBS. The appropriate 
colony-forming units (CFU)/ml for a microbe was the concentration producing sufficient growth on 
pure agar plates when inoculated with a 20 µl spot and incubated at 37 °C for 24 hours. According 
to this suspensions were adjusted to approximately 2 × 106 CFU/ml for C. albicans, 2 × 104 CFU/ml 
for E. coli, 2 × 105 CFU/ml for S. aureus, 8 × 105 CFU/ml for S. epidermidis and 6 × 105 CFU/ml 
for S. pyogenes using a turbidimeter (DEN-1 McFarland Densitometer, Biosan).  
The surface of the agar plates were inoculated with a 20 µl spot using a replicator and incubated at 
37°C for 24 h. MIC was the lowest concentration of the formulation/substance inhibiting growth 
determined by visual inspection. MIC for the active substance as part of a cream was calculated as 
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the concentration of active substance in the cream multiplied by the MIC for the entire cream.  
 
Limitations of the in vitro model 
When reviewing the results of paper III it is important to consider that in vitro results cannot always 
be extrapolated to the in vivo situation. The in vitro and in vivo milieu can differ greatly with 
regards to factors such as pH, salt concentrations and temperature. A potential weakness with the 
agar dilution assay is the heating of the formulation which occurs when it is dissolved in the agar. 
When agar plates are made the formulation or substance is dissolved in liquid agar which keeps a 
temperature of 48-50°C as described.  The agar has to keep this temperature during dissolving 
because it sets quickly when cooled below 45°C. The agar, with the dissolved formulation, is 
immediately poured into Petri dishes at room temperature where it quickly cools and sets. As a 
consequence, all formulations tested have briefly reached a temperature which is above body 
temperature and higher than that recommended for storage. It is possible that this heating affects 
properties of the formulations. 
Considering these limitations, the MIC value for a formulation needs to be viewed in relation to 
MIC values obtained for other formulations with the same assay and, most importantly, in relation 
to clinical experience. 
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PAPER IV 
 
Quantitative culture for S. aureus 
Quantitative culture from the skin surface allows for determination of the density of a particular 
microbe expressed as CFU/cm2.  
Quantitative cultures for S. aureus were obtained from representative sites of lesional and 
uninvolved skin at all patients’ visits during follow-up. Sampling and culture was performed at the 
Department of Dermatology, Sahlgrenska University Hospital. The method was an adaptation of 
methods previously described [163, 164].  
A stainless steel ring with an inner area of 5.5 cm2 was placed on the skin and held in place with 
moderate pressure by two fingers (Figure 6). One milliliter of dispersed detergent (PBS, pH 7.9, 
with 0.1% Triton X-100) was applied onto the skin circumscribed by the ring. Diluted Triton X-100 
helps suspend bacteria to single cells without damaging their cell membranes. The skin was then 
rubbed with a glass rod for exactly one minute. The microbe-containing suspension was then 
aspirated and aliquoted. Serial ten-fold dilutions (undiluted to 1:100 000) were immediately 
prepared. 100 µl of each dilution was plated on individual blood agar plates (Columbia agar (Oxoid, 
Basingstoke UK) + 5% defibrinated horse blood). Plating serial dilutions of the microbe suspension 
ensured that there would be plates with an appropriate number of colonies for manual counting. 
Plates were incubated for 24-48 hours in 37°C.  
All morphologically different colonies found on the plates after incubation were counted separately 
and tested with Slidex® Staph Plus (Biomérieux, Lyon, France), a rapid S. aureus-specific 
agglutination test. All Slidex® Staph Plus-positive isolates were verified with the tube coagulase 
test. The density of S. aureus on the skin expressed as CFU/cm2 was calculated. 
 
 
 
All S. aureus isolates were cultured on new blood agar plates for purity. Isolates were then kept in 
freezing medium at -80°C. 
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Figure 6. Quantitative culture for S. aureus. 
A. 1 mL Triton X 0.1% in PBS applied onto skin. B. Skin is rubbed for one minute with a glass rod. 
C+D. The aspirate is plated on blood agar plates. E. Multiple colonies after incubation. F. Slidex® 
Staph Plus shows agglutination for S. aureus colony. Photo: Mikael Alsterholm and Lina Hagvall 
 
 
Considerations regarding sampling site 
For several reasons, the preferred sampling site for quantitative S. aureus culture was the arm. In 
adult patients with AD both lesional skin and uninvolved skin is often present on the arms. The arm 
is also a body part where the stain-less steel ring used for sampling is easily applied and held in 
place. Since S. aureus colonization rates vary depending on body site it was important to keep 
sampling within the same body area, whenever possible, in order to avoid over- or underestimation 
of differences between lesional and uninvolved skin. Other body sites were sampled when there 
were no representative areas of lesional or uninvolved skin on the arms; preferably the trunk or 
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upper leg. The meticulous sampling technique for quantitative culture proved highly sensitive. In 
fact, we took conventional swabs for qualitative culture on skin immediately adjacent to the 
sampling sites for the quantitative cultures. The S. aureus detection level was lower for swab 
samples than for the quantitative cultures (data not shown). 
 
Qualitative culture for S. aureus  
Swab samples for S. aureus cultures were secured from the anterior nares, tonsils and perineum at 
each visit. Swab samples were also taken from the body sites where quantitative cultures were 
obtained for comparison of the detection level of the two techniques as described above. Cultures 
were made at the Department of Microbiology, the Sahlgrenska Academy at the University of 
Gothenburg.  
S. aureus isolates were verified with Slidex® Staph Plus and the tube coagulase test, re-cultured for 
purity on blood agar plates and kept in freezing medium at -80°C.  
 
Pulsed-field gel electrophoresis (PFGE) 
All S. aureus isolates found on lesional skin, in the anterior nares and perineum (n = 94) and 
twenty-five S. aureus isolates found on uninvolved skin were typed for strain identity with PFGE. 
Low counts of S. aureus on uninvolved skin in the absence of S. aureus on lesional skin were not 
typed.  
We chose to type for strain identity with PFGE because the primary aim was to establish isolate 
interrelationships and because PFGE remains the gold standard in clinical bacteriology [165]. 
S. aureus isolates were grown on blood agar plates over night. Ten colonies were suspended in 500 
µl TEN-buffer (Trizma® HCL (Sigma T3253), EDTA (Titriplex II Merck 8417), sodium 
desoxycholate (Merck 6504)), the suspension centrifuged (13 000 G, 20 seconds) and the 
supernatant discarded. The bacteria were re-suspended in 125 µl EC-buffer (Trizma® HCl (Sigma 
T3253), sodium chloride (Fischer Scientific), EDTA (Titriplex II Merck 8417, polyoxyethylene 20 
cetyl ether (Sigma P5884), sodium deoxycholate (Merck 6504), N-laurylsarcosyl (Sigma L5125)). 
The suspensions were placed on a heating block set to 56°C for 15 minutes and 12 µl Lysosome A 
(0.5 u/µl, Sigma Aldrich) was added. Plugs were created by adding 125 µl 2% low-melting-point 
agarose to each suspension (Sigma Aldrich) and pipetting 125 µl of the resulting mix into plug 
molds. Plugs were kept at 5°C for 15 minutes and then incubated at 37°C for one hour in tubes 
containing 1 ml EC-buffer. Subsequently, plugs were sliced in half and placed in tubes containing 
250 µl TE-buffer (Trizma® HCl (Sigma T3253), EDTA (Titriplex II Merck 8417)) and 25 µl protein 
kinase K (5 mg/ml) (Roche Applied Science). Plugs were then incubated with fresh TE-buffer at 
5°C for ten minutes and this washing step was repeated six times.  
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The bacterial DNA was digested with 20 units of smaI enzyme in 200 µl of the corresponding 
restriction enzyme buffer and separated by electrophoresis with the Gene Path system (Bio-Rad 
Laboratories, Sweden). Total runtime was 23 hours. The first block switch time was 5-15 seconds 
for 10 hours and the second block switch time was 15-60 seconds for 13 hours. The voltage for the 
run was 6 V/cm or 200 V. The included angle was 120°. The ramp factor was linear. After 
completed runtime, gels were stained in ethidiumbromide (1µg/ml) followed by destaining for one 
hour or more in 500 ml distilled water.  
The digital comparison of profiles was made with the BioNumerics software (Version 6.6; Applied 
Maths, St-Martens-Latem, Belgium). Cluster analysis of Dice similarity indices based on the 
unweighted- pair group method using average linkages (UPGMA) was used to generate a 
dendrogram describing the relationships among PFGE profiles. Isolates were considered to belong 
to the same PFGE group if their Dice similarity index was ≥ 80%.  
 
Carriage patterns of S. aureus strains on lesional skin were analyzed.  
Persistent carriage was defined as S. aureus-positive with same strain at three visits or same strain at 
two visits and negative at remaining visit.  
Intermittent carriage was defined as S. aureus-positive with low counts at one visit, negative at 
remaining visits.  
Non-carriage was defined as S. aureus-negative at all three visits.  
 
 
STATISTICS 
 
All data were analyzed using R version 2.14.2 or previous versions (The R Foundation for 
Statistical Computing, Vienna, Austria) [166].  
 
Paper I 
The frequencies of microbes in the balanoposthitis group and in the control group were compared 
with Fisher’s exact test. The same statistical instrument was used to compare prevalence of 
seborrhoeic dermatitis between groups. The significance level was p < 0.05. 
 
Paper II 
The statistical test used to compare frequencies of FRSA between groups was Fisher’s exact test. 
The significance level was p < 0.05. 
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Paper III 
No statistical calculations were used in the interpretation and presentation of the data. 
 
Paper IV 
Comparison of S. aureus density on lesional and uninvolved skin was made with Wilcoxon sign-
rank test. Mean objective SCORAD index for persistent S. aureus carriers and non- or intermittent 
carriers was compared with Wilcoxon rank-sum test. Correlation between the density of S. aureus 
on lesional skin and objective SCORAD index was analysed with linear regression. The number of 
S. aureus-positive body sites was related to objective SCORAD index with generalized least square 
regression. The significance level was p < 0.05.  
 
 
ETHICAL APPROVAL 
 
Paper I, II and IV 
The design of the studies presented in papers I, II and IV were all individually reviewed and 
approved by the Ethics Committee at the University of Gothenburg. Participants received oral and 
written information about the studies before their written consent was obtained.  
 
Paper III 
For paper III no ethical approval was required since the study did not involve patients, patient data 
or animals. 
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SUMMARY OF RESULTS AND DISCUSSION 
 
PAPER I 
 
A total of 102 patients with clinical signs of balanoposthitis and 26 control patients were examined. 
Investigation revealed that one patient from the balanoposthtitis group suffered from Zoon balanitis 
and another from HSV type 2.  The data of these two patients are not included in the following 
since Zoon balanitis and viral aetiology were outside the scope of the study. 
 
General microbial colonization 
Overall, we found that microbial colonization was more frequent in the area of the prepuce and 
glans penis in patients with balanoposthitis than in the control group (59% and 35%, respectively, p 
< 0.05).  S. aureus was found in 19 % of patients in the balanoposthitis group and in none of the 
control patients, p < 0.05. Results are summarized in Table II.  
 
 
 
 
Balanoposthitis group 
n = 100 
Control group   
n = 26 
S. aureus 19 (19%) *  - 
Group B streptococci 9 (9%) 1 (3.8%) 
Group C streptococci 3 (3%) - 
C. albicans 18 (18%) 2 (7.7%) 
Malassezia species 23 (23%) 6 (23%) 
 
Table II. Frequency of bacteria and yeasts in balanoposthitis and in the control group. 
*p < 0.05 
Modified from Alsterholm et al [154] (= paper I) with permission from the publisher. 
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C. albicans 
We found no increase in C. albicans (or group B streptococci) in patients with balanoposthitis 
compared with controls (Table II, Table III). No other Candida species than C. albicans were 
detected.  
 
 Balanoposthitis group   
n = 100 
Control group   
n = 26 
C. albicans   
Heavy growth  10 (10%) - 
Moderate growth  8 (8%) 2 (7.7%) 
 
Table III. Quantification of growth of C. albicans in patients with balanoposthitis and in the control 
group. 
Modified from Alsterholm et al [154] (= paper I) with permission from the publisher. 
 
 
This result is in contrast with previous investigators, who have reported C. albicans, followed by 
group B streptococci, to be the most common microbe in balanoposthitis. Only two previous studies 
have included a control group for comparison and they report the prevalence of C. albicans in 
balanoposthtitis to 30-31% [51, 52]. Age range and rate of circumcision were similar in our study 
and the studies of others and cannot explain the difference.  
In our study the growth of C. albicans was visually quantified. We found very discrete or discrete 
growth of C. albicans in 13 additional patients in the balanoposthitis group and in 2 additional 
patients in the control group (not displayed in Table III). We felt that the clinical importance of very 
discrete or discrete growth of C. albicans was uncertain, especially since colonization of the sulcus 
coronarius is frequent in asymptomatic men [68, 69]. Therefore we chose to present statistics based 
only on patients with moderate and heavy growth of C. albicans in paper II. Even if we include the 
patients with very discrete and discrete of C. albicans in our statistical analysis we do not reach a 
significant difference in the frequency of C. albicans between the balanoposthitis group and the 
control group (31% vs 15%, p = 0.14). Previous investigators do not describe or consider 
quantification of C. albicans and this could possibly lead to an overestimation of clinical 
significance. 
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Malassezia species 
There was no difference in the frequency of Malassezia species between groups (Table II). Five 
different Malassezia species were found (Table IV).  
 
 Balanoposthitis group   
n = 100 
 Control group   
n = 26 
 > 5 col. 2-5 col. 1 col.  > 5 col.  2-5 col.  1 col.  
M. globosa - 5  3  - - 1 
M. obtusa 1 4 2  - - 1 
M. sympodialis - - 3  - - 2 
M. obtusa + M. globosa 1 1 -  - - - 
M. obtusa + M. sympodialis - 1 -  - - - 
M. obtusa + M. restricta 1 - -  - - - 
M. sympodialis + M. restricta - 1 -  1 - - 
M. globosa + M. slooffiae - - -  1 - - 
 
Table IV. Frequency, distribution and quantification of Malassezia species in the balanoposthitis 
and control groups. 
 
For each Malassezia species quantification and number of patients are shown. When more than one 
Malassezia species was detected the combined number of colonies is presented. 
Modified from Alsterholm et al [154] (= paper I) with permission from the publisher. 
 
 
Observations of Malassezia species were too few to establish if the distribution of species differed 
between groups. The most commonly found species appeared to be M. globosa and M. obtusa.  
For the differentiation of M. obtusa and M. sympodialis growth at 38°C in a Dixon medium is used 
(Figure 4, page 51). During the study, this step proved to be unexpectedly sensitive to the general 
state of the medium (date of preparation, viscosity). Therefore, we cannot exclude that some of the 
isolates have been incorrectly identified as M. obtusa while they in fact were M. sympodialis. 
Assuming that we, due to these methodological issues, have underestimated the number of M. 
sympodialis isolates in favour of M. obtusa, we find that M. globosa and M. sympodialis might have 
been two of the most common isolates among our patients. This would be similar to the results of 
Mayser et al who described the frequency and spectrum of Malassezia species in the area of the 
prepuce and glans penis in healthy men, a majority of which were uncircumsized. The most 
common isolates in that study were M. sympodialis and M. globosa [49].  
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The lack of overrepresentation of Malassezia species in our study does not necessarily rule out a 
role for this yeast in the aetiology of balanoposthitis. The association between specific Malassezia 
species, the amount of those species on the skin and diseases like pityriasis versicolor and 
seborrhoeic dermatitis has proven to be complicated and incompletely understood [40]. For 
instance, patients with seborrhoeic dermatitis have been shown to harbour increased, decreased or 
unchanged levels of yeasts on lesional skin compared with uninvolved skin [47, 167]. It has been 
proposed that in those skin diseases where the association with Malassezia is clearly established, e. 
g. seborrhoeic dermatitis, the host immunological response to the yeast is of importance [168]. In 
seborrhoeic dermatitis, treatment to reduce Malassezia yields a parallel improvement of symptoms 
[169]. Suggested ways for Malassezia to induce symptoms are through precipitating antibodies 
against the yeast, production of toxin, lipase activity and activation of complement [170, 171]. 
 
S. aureus 
In the balanoposthitis group 19% of patients exhibited S. aureus in the area of the prepuce and glans 
penis while no S. aureus were found in the control group (p < 0.05) (Table II). 
 
An overrepresentation of S. aureus has not been described in any previous study on the microbial 
flora of balanoposthitis. In fact, S. aureus has rarely been detected at all. This is somewhat 
surprising since S. aureus is a very common skin pathogen as well as a commensal. In the general 
population, 22% of adults are colonized in the perineum, a number rising to 60% for those who are 
nasal carriers of  S. aureus [12].  
There are several possible explanations for the difference in S. aureus prevalence in our and other 
comparable studies [51-54]. 
 
• The definition of balanoposthitis in our study could differ from the definitions used by 
others and this could in turn influence the microbiological data. There are no universally 
acknowledged criteria for the diagnosis balanoposthitis, nor is there a scoring system to 
grade severity. Most patients attending our clinic present with mild to moderate 
balanoposthitis. We suggest that mild to moderate balanoposthitis in many cases is caused 
primarily by irritants such as excessive hygiene, frequent sexual intercourse or other 
dehydrating or abrasive trauma to the prepuce and glans penis. This association has been 
described by others [60]. Dehydrated or otherwise irritated skin could be vulnerable to 
colonization with microbes that can maintain or increase inflammation. A probable 
candidate for colonization would be S. aureus, explaining why we find a high percentage of 
this staphylococcus in our study. 
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• Individual patient factors, i.e. diabetes, obesity, personal hygiene customs and sexual habits 
were not described by us or others. Differences in such factors might explain why we find 
and increased rate of S. aureus (and no increase in C. albicans) in contrast with other 
studies. Another factor to consider in this context is climate. Our studie was performed in a 
relatively cold climate. The microbial panorama of balanoposthitis might be different in hot 
and humid climates. 
• Another possible explanation for the increased isolation rate of S. aureus could be that the 
frequency and distribution of microbes in any population are not constant. Community 
patterns of antibiotic consumption, the use and composition of hygiene products as well as 
sexual habits change and can in turn alter the composition of the microbiome. The 
comparable studies of microbes in balanoposthitis were published in the years 1983-1995 
and might represent a microbial milieu that has now evolved [51-54].  
• The increased rate of S. aureus could also be due to a hypothetical higher rate of patients 
with atopy in our study compared to others. An association between balanoposthitis and AD 
has been suggested [60].  In retrospect, we regret not taking a patients’ history regarding AD 
and other manifestations of atopy. Patients with AD are frequently colonized with S. aureus 
and the skin lesions of balanoposthitis and AD are similar. Balanoposthitis could in some 
cases be a manifestation of AD and S. aureus colonization would be expected. 
 
Normal bacterial skin flora 
41% of patients in the balanoposthitis group and 65% of patients in the control group exhibited no 
S. aureus or group B/C streptococci and no growth of Candida or Malassezia species. Cultures from 
these patients showed normal bacterial skin flora which was defined as one or several of alpha 
streptococci, CoNS, Corynebacterium species, enterococci, E. coli, gram-negative mixed flora or 
gram-positive mixed flora. 
 
The association between clinical presentation and different microbes 
Clinical findings were similar among patients in the balanoposthitis group, irrespective of microbe. 
Erythema of the prepuce and/or glans penis was the most common finding (83%) followed by 
papules (48%), transudation (30%) and white membranes (27%).  
In this material there was no correlation between clinical findings and specific microbes. The 
clinical presentation of balanoposthitis did not predict the presence or absence of microbes or the 
type of microbe present in the preputial sac or on the glans penis. Candida infection of the skin is 
sometimes associated with pustules. It has been shown that the presence of pustules in 
balanoposthitis is highly suggestive of Candida [51]. This was not replicated in our study. In fact, 
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pustules were rare, present in only five patients, two of whom presented with C. albicans. 
The presence of a particular microbe was not correlated with the number of clinical criteria noted in 
an individual patient, meaning it was not apparent that any of the microbes were associated with a 
more severe clinical picture (data not shown). 
 
The association between balanoposthitis, seborrhoeic dermatitis and psoriasis 
No association between balanoposthitis and seborrhoiec dermatitis or psoriasis could be 
demonstrated.  
Patients with balanoposthitis reported a similar frequency of seborrhoeic dermatitis compared with 
controls, 29/100 patients (29%) and 9/26 patients (35%), respectively. Clinical findings of 
seborrhoeic dermatitis at time of visit were present in 13/29 (45%) of those patients with 
balanoposthitis who reported ever having seborrhoeic dermatitis and in 3/9 (33%) of those control 
patients who reported ever having seborrhoeic dermatitis.  
Patients with balanoposthitis were subdivided based on the results of the cultures. The frequency of 
seborrhoeic dermatitis was not significantly higher in any of the subgroups (44% of patients with 
Malassezia vs 5.4% of patients with C. albicans vs 26% of patients with S. aureus, NS). The 
observed Malassezia isolates were too few to establish whether one or several species were 
associated with balanoposthitis and or seborrhoeic dermatitis. 
There was no patient with active psoriasis in the study but one patient in the balanoposthits reported 
previous psoriatic skin lesions.  
 
Conclusion 
For the first time, the spectrum of bacteria, Candida and Malassezia species in patients with 
balanoposthitis and a control group is described. There was a significantly higher frequency of 
microbes in the area of the prepuce and glans penis in the balanoposthitis group compared to the 
control group. S. aureus was found in 19% of balanoposthitis patients but not at all in the control 
group. An increase in C. albicans in balanoposthitis, previously described by others, was not 
confirmed. Clinical findings did not predict presence of specific microbes. There was no association 
between balanoposthtitis and seborrhoeic dermatitis or psoriasis.  
  
Our findings and the results of other investigators suggest that patients with mild to moderate 
balanoposthitis are vulnerable to colonization with microbes in the area of the prepuce and the glans 
penis. We propose that the condition reflects an increased susceptibility to irritants causing 
dermatitis and subsequent colonization with microbes. These microbes could increase and maintain 
pre-existing inflammation. The irritants could be excessive hygiene habits or repeated minor 
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abrasive trauma during sexual intercourse. 
The primary therapeutic target in mild to moderate cases of balanoposthtitis should be to decrease 
inflammation with a mild topical corticosteroid (group I or II). The addition of antimicrobial agents 
to the topical preparation can reduce microbial load and thereby probably increase the anti-
inflammatory effect. It is interesting that some azoles, for instance miconazole, in addition to their 
effect on yeasts are active against S. aureus and S. epidermidis in vitro (shown and discussed in 
paper III). In our clinic, tapered topical hydrocortisone-miconazole or triamcinolone-econazole 
application (twice daily for one week, once daily for one week and once every other day for one 
week) is generally effective. In severe cases of balanoposthitis systemic antibiotics are sometimes 
needed to resolve symptoms.  
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PAPER II 
 
Bacterial spectrum in prospective study 2004-2008 
Thirty-eight patients with impetigo and 37 patients with secondarily infected AD were included in 
the study.  
S. aureus was by far the most common bacteria found in cultures from skin lesions in impetigo and 
AD (76-93%) (Table V, Table VI).  
 
 Impetigo 
 n = 25 
Bullous impetigo  
n = 13 
S. aureus 17 (68%) 11 (85%) 
Methicillin-resistant S. aureus (MRSA) 1 (4.0%) - 
S. aureus + Group A streptococci 1 (4.0%)  1 (7.6%) 
Coagulase negative staphylococci 2 (8.0%)  - 
Bacillus cereus 1 (4.0%)  - 
Normal skin flora 1 (4.0%)  - 
Negative culture 2 (8.0%)  1 (7.6% 
 
Table V. Prospective study 2004-2008. Frequency and distribution of bacteria in impetigo and 
bullous impetigo.  
For each bacteria/group of bacteria the number of patients is presented. 
Modified from Alsterholm et al [172] (= paper II) with permission from the publisher. 
 
 Secondarily infected AD  
n = 37 
S. aureus 28 (76%) 
Methicillin-resistant S. aureus (MRSA) 1 (2.7%) 
S. aureus + Group A streptococci  3 (8.1%)  
S. aureus + Group C streptococci  1 (2.7%)  
Coagulase negative staphylococci 2 (5.4%)  
Negative culture 2 (5.4%)  
 
Table VI. Prospective study 2004-2008. Frequency and distribution of bacteria in secondarily 
infected AD.  
For each bacteria/group of bacteria the number of patients is presented. 
Modified from Alsterholm et al [172] (= paper II) with permission from the publisher. 
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FRSA in prospective study 2004-2008 
FRSA were a frequent finding in impetigo, particularly bullous impetigo, but less common in AD. 
Specifically, 75% of S. aureus isolates were fusidic-acid resistant in bullous impetigo, 32% in 
impetigo and 6.1% in secondarily infected AD. There was a statistically significant difference 
between groups (Figure 7). 
 
 
Figure 7. Prospective study 2004-2008. Frequency (%) of fusidic acid-resistance in S. aureus-
isolates from patients with impetigo, bullous impetigo or secondarily infected AD. 
Frequency of FRSA was compared between groups with Fisher’s exact test. Values are presented 
with a 95% confidence interval. Significance level was p < 0.05. 
From Alsterholm et al [172] (= paper II) with permission from the publisher. 
 
 
Bacterial spectrum in the patient record review 
S. aureus was by far the most common bacteria found in cultures from skin lesions in impetigo (76-
88%) and AD (78-84%) (Table VII, Table VIII). Bacterial spectrum and frequency of S. aureus 
isolates were similar in the prospective study and the patient record review.  
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 Impetigo 
 June 2004-May 2005  
n = 66 
June 2007-May 2008  
n = 33 
S. aureus 45 (68%) 21 (64%) 
Methicillin-resistant S. aureus (MRSA) - 1 (3.0%) 
S. aureus + Group A streptococci  2 (3.0%)  
S. aureus + Group B streptococci  5 (7.6%) 2 (6.1%) 
S. aureus + Group G streptococci - 1 (3.0%) 
S. aureus + other bacteria 6 (9.1%) - 
Coagulase negative staphylococci 2 (3.0%) 2 (6.1%) 
Group A streptococci 1 (1.5%) 1 (3.0%) 
Bacillus cereus 1 (1.5%) - 
Other bacteria - 2 (6.1%) 
Negative culture 4 (6.1%) 3 (9.1%) 
 
 
 Secondarily infected AD 
 June 2004-May 2005  
n = 55 
June 2007-May 2008  
n = 55 
S. aureus 30 (55%) 22 (40%) 
Methicillin-resistant S. aureus (MRSA) 1 (1.8%) 1 (1.8%) 
S. aureus + Group A streptococci  3 (5.5%) 6 (11%) 
S. aureus + Group B streptococci 2 (3.6%) 8 (15%) 
S. aureus + Group C streptococci  2 (3.6%) 1 (1.8%) 
S. aureus + Group G streptococci 2 (3.6%) 5 (9.1%) 
S. aureus + Group A & G streptococci  - 1 (1.8%) 
S. aureus + other bacteria 3 (5.5%) 2 (3.6%) 
Group G streptococci - 1 (1.8%) 
Coagulase negative staphylococci 5 (9.1%) 2 (3.6%) 
Other bacteria 3 (5.5%) 3 (5.5%) 
Negative culture 4 (7.3%) 3 (5.5%) 
 
Table VII and VIII. Patient record review. Frequency and distribution of bacteria in impetigo (VII) 
and secondarily infected AD (VIII). 
For each bacteria/group of bacteria the number of patients is presented. 
Modified from Alsterholm et al [172] (= paper II) with permission from the publisher. 
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FRSA in the patient record review 
In the time period June 2004 to May 2005 33% of S. aureus isolates found in impetigo were fusidic 
acid-resistant whereas the corresponding number for S. aureus isolates found in secondarily infected 
AD was 12%. In the time period June 2007 to May 2008 24% of S. aureus isolates found in 
impetigo were fusidic acid-resistant whereas the corresponding number for S. aureus isolates found 
in secondarily infected AD was 2.2% (Figure 8). These results were similar to those of the 
prospective study. 
 
 
Figure 8. Patient record review. Frequency (%) of fusidic acid-resistance in S. aureus-isolates from 
patients with impetigo or secondarily infected AD.  
Frequency of FRSA was compared between groups with Fisher’s exact test. Values are presented 
with a 95% confidence interval. Significance level was p < 0.05. 
From Alsterholm et al [172] (= paper II) with permission from the publication. 
 
 
It is important to point out that the patients in this study represent a selected group of impetigo and 
AD patients in the sense that they have been referred to an outpatient dermatology clinic. Mild 
cases of impetigo and secondarily infected AD are often treated by general practitioners and other 
health care professionals. This means that the patients in our study do not necessarily represent the 
spectrum of impetigo and secondarily infected AD in the general population. For instance, bullous 
or extensive lesions could be a clinical presentation of impetigo suggesting differential diagnoses 
and could make a general practitioner more inclined to refer the patient to a dermatologist. While 
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we note that a similar study in a primary health care setting might have rendered another result, it 
appears unlikely that the frequencies of FRSA in our study are an underestimation of those in the 
general population. 
 
In our clinical setting, the prospective study did not seem to reflect a biased selection of patients. 
The patient record review gave a similar result regarding age-distribution, bacterial spectrum and 
frequency of fusidic acid-resistance in S. aureus isolates. 
 
S. aureus was, unsurprisingly, the most common finding in non-bullous impetigo, bullous impetigo 
and secondarily infected AD, constituting over 75% of isolates. Fusidic acid-resistant isolates of S. 
aureus were a frequent finding in bullous impetigo. This is consistent with the established 
association between FRSA, production of exfoliative toxin and bullous impetigo lesions [112]. 
However, FRSA were also cultured from lesions of clinically non-bullous impetigo and a small 
fraction of infected AD lesions. This demonstrates that FRSA infection is not always associated 
with blistering skin disease.  
 
The patient record review indicated a decline in the proportion of FRSA isolates from 2004 to 2008 
(from 33% to 24% for impetigo and from 12% to 2.2% for secondarily infected AD, NS). A 
statistically significant change in the same direction is documented in the well defined population of 
the Norwegian island community Austevoll where impetigo and FRSA incidence is continuously 
monitored. A gradual decrease in impetigo-derived S. aureus isolates resistant to fusidic acid was 
recorded from 2001 to 2009 [74].  
National data on the proportion of FRSA among SSTI-derived S. aureus isolates from Norway and 
Sweden also show a decline. The Norwegian Surveillance System for Antimicrobial Resistance 
demonstrated that the proportion of FRSA from SSTIs was steadily falling from 25% in 2004 to 
10% in 2008 [173]. Data from the Swedish surveillance system ResNet showed the same trend but 
on a lower scale [144]. Swedish FRSA levels peaked at 9.6% in 2002, declined to 3.8% in 2005 and 
stabilized at 4.0-6.0% in the years that followed. 
Although FRSA levels seem to decline it is noteworthy that resistance against fusidic acid remains 
the most prevalent antibiotic resistance in the panel of antibiotics tested on S. aureus isolates 
reported to ResNet (page 35) [144]. 
 
In addition to investigating fusidic acid-resistance in S. aureus isolates derived from lesions of 
impetigo this study focused on the less investigated prevalence of FRSA in secondarily infected 
AD. The atopic skin is highly susceptible to colonization with S. aureus. We speculated that patients 
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with AD could be at risk of becoming carriers of fusidic acid-resistant clones of S. aureus, in turn 
serving as community reservoirs and increase further spread. With the high prevalence of both 
impetigo and AD in young children, FRSA could rapidly become widespread through daycare 
centers and schools.  
In contrast to this proposed scenario, the results show a low frequency of fusidic acid-resistance 
among S. aureus isolates from patients with secondarily infected AD. Encouragingly, the frequency 
remained low during 2004-2008 and there was even indication of a decline. This was in contrast 
with the trend indicated by scattered European reports from the mid-90s and onward where FRSA 
were found in up to 50% of patients [136, 141-143]. One reason for the low rates of FRSA in AD in 
our study is probably the restrictive use of topical fusidic acid implemented in Sweden in 2003 [75, 
138]. There could also have been differences between Sweden and other European countries in the 
pattern of prescription and use of fusidic acid prior to 2003. Increased use of topical fusidic acid in 
the community promotes the emergence of resistant strains. Conversely, limitations in use have 
been followed by declining FRSA levels [134-137]. 
Table IX illustrates topical fusidic acid sales and FRSA levels in Sweden in the years following our 
study. The comparatively low and stable frequency of fusidic acid- resistance among S. aureus 
isolates from SSTIs has been paralleled with diminishing national sales of fusidic acid cream and 
ointment. 
  
 Sales of fusidic acid cream and ointment 
(number of 15 g packs*) 
FRSA 
(% of total S. aureus isolates) 
2008 58539 5.3 
2009 53076 4.7 
2010 50030 6.2 
2011 44833 6.0 
2012 40700** 4.8*** 
 
Table IX. Swedish sales of fusidic acid cream and ointment and FRSA reported to ResNet 2008-
2012. 
Sales data available on request from Apotekens Service: statistic@apotekensservice.se 
* Fusidic acid cream and ointment are available in 15 g and 30 g packs, numbers have been 
recalculated to 15 g packs.  
** Estimated value for entire year, report available for January to August (27248). 
*** Report currently available from 12 out of 29 reporting laboratories. 
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It is difficult to determine to what extent a decline in total FRSA levels depends on restrictive use of 
topical fusidic acid and what is attributable to the normal dynamics of an epidemic. In the patient 
record review we found 101 cases of impetigo in the first year but only 53 cases in the last year.  In 
similarity, there is data from Austevoll showing a decrease in the incidence of impetigo between 
2001 and 2009. Given that impetigo remains the SSTI primarily associated with FRSA, fewer 
impetigo cases would also mean a decrease in the total number of FRSA isolates. While the 
incidence of impetigo and, as a consequence, total FRSA levels in Austevoll have faded, the 
percentage of FRSA isolates has remained high among impetigo cases. In 2008, 44% of S. aureus 
isolates from impetigo lesions were fusidic acid-resistant and 89% of those isolates belonged to the 
EEFIC [74]. 
One lesson we learned during the patient record review was that in many cases no bacterial cultures 
were secured from patients with impetigo or secondarily infected AD. The reason for this is 
probably that dermatologists are aware that in a vast majority of cases these conditions are caused 
by S. aureus. There is however another increasingly important reason for collecting swabs for 
bacterial cultures: monitoring of trends in antibiotic resistance. Sweden has excellent surveillance of 
antibiotic resistance on a national and regional level, comparatively low frequencies of multi-
resistant bacteria in both outpatient and inpatient care and the authorities work actively to reduce 
non-evidence based prescription of antibiotics. To compliment this, clinicians need to be vigilant of 
emerging antibiotic resistance in bacterial strains from specified patient groups. 
It appears widely accepted that long term treatment with topical antibiotics should be avoided as it 
can select for resistant strains [174]. For instance, topical mupirocin for SSTIs has promoted 
resistance in S. aureus and CA-MRSA [175, 176]. In contrast, short duration topical antibiotic 
therapy remains controversial [152]. Fusidic acid teaches us that widespread use of brief courses 
can promote resistance on a community level. 
 
Conclusion 
Management of impetigo and other SSTIs is possible without the use of topical fusidic acid 
formulations. Fusidic acid resistance remains a common form of antibiotic resistance among S. 
aureus isolates in Sweden. There is strong evidence that the community pattern of topical fusidic 
acid use influences the proportion of FRSA isolates cultured from patients with impetigo and other 
SSTIs. Fusidic acid is an antibiotic that, due to its unique mechanism of action, does not exhibit 
cross-resistance with β-lactam antibiotics. Fusidic acid can therefore be effective against MRSA and 
may become an increasingly important systemic antibiotic in the years to come [118]. Rapidly 
increasing antibiotic resistance is a global health threat and in view of that it seems wise not to 
waste fusidic acid. Indiscriminate use could potentially make this antibiotic worthless. 
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PAPER III 
 
The in vitro antimicrobial properties of commonly used topical skin pharmaceuticals and their 
active substances, expressed as MIC-values against selected microbes were investigated with agar 
dilution assay. Table X provides an overview of the results to the help the reader follow the 
discussion. Tables XI-XV show the results in more detail. 
 
Antibiotic formulation and substance 
The MICs for Fucidin® 2% cream (fusidic acid) and fusidic acid are presented in Table XI. The 
strongest activity was, as predicted, seen against S. aureus and S. epidermidis (MIC 0.1 µg/ml for 
fusidic acid as part of the cream or alone and 5 µg/ml for the entire cream), but there was also an 
effect on S. pyogenes (MIC 10 µg/ml for fusidic acid as part of the cream, 6.25 µg/ml for fusidic 
acid alone and 500 µg /ml for the entire cream). Fusidic acid did not inhibit growth of C. albicans 
or E. coli. 
Fusidic acid is primarily an anti-staphylococcal drug, but activity against streptococci has been 
described in vitro. In an evaluation of 242 strains of streptococci isolated from SSTIs, MIC levels 
ranged from 8 mg/l to 16 mg/l for fusidic acid [177]. In our study, MIC for fusidic acid as part of 
cream against S. pyogenes is equivalent to 10 mg/l and MIC for fusidic acid tested as active 
substance alone is equivalent to 6.3 mg/l. It is possible that fusidic acid can have a clinically 
relevant activity against streptococci when used as a topical preparation. In comparison, skin 
concentrations after twice daily oral administration of 500 mg fusidic acid are reported to be 39-79 
mg/l which could explain a described clinical effect [178]. However, development of resistance 
against fusidic acid in S. aureus, argues against the use of topical fusidic acid formulations as 
discussed in paper II. 
 
Antifungal formulations and substances 
Clotrimazole as part of Canesten® 1% and miconazole nitrate, econazole nitrate and terbinafine 
hydrochloride were effective against C. albicans (MICs 3.125–25 µg/ml) (Table XII). 
Miconazole in Daktar® 2% and Daktacort® had a high MIC against C. albicans (1000 µg/ml for 
miconzole as part of the cream, 50,000 µg/ml for the entire cream) compared with miconazole 
nitrate alone (MIC 3.1 µg/ml). The same pattern was noted for terbinafine in Lamisil® 1% (MIC 
2000 µg/ml for terbinafine as part of the cream, 200,000 µg/ml for the entire cream) and terbinafine 
hydrochloride alone (MIC 25 µg/ml).  
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 C. albicans E. coli S. aureus S. epidermidis S. pyogenes 
Fucidin® - - +++ +++ ++ 
Fusidic acid - - +++ +++ ++ 
Canesten® + - +++ +++ - 
Daktar® - - +++ +++ - 
Daktacort® - - +++ +++ - 
Miconazole nitrate ++ ND +++ +++ ++ 
Lamisil® - - - - ++ 
Terbinafine HCl ++ ND - - - 
Econazole nitrate +++ ND +++ +++ ++ 
Ketoconazole ++ ND ++ ++ ND 
Microcid® - ++ +++ +++ ++ 
Hydrokortison CCS® - - - - - 
Emovat® - - - - - 
Betnovat® - - - - - 
Dermovat® - - - - - 
Betnovat® with chinoform ++ ++ ++ ++ + 
Clioquinol ++ ++ ++ ++ ND 
Kenacutan® ++ ++ ++ ++ NA 
Table X. Overview of in vitro antimicrobial activity of topical skin pharmaceuticals.  
Arbitrarily choosen ranges of activity: +++ MIC < 2 µg/ml (for active substance as part of cream or active substance alone), ++ MIC 2-50 µg/ml, + 
MIC > 50 µg/ml, - MIC > 1000 µg/ml. ND = not determinable. NA = not analyzed.
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Clotrimazole, miconazole and econazole nitrate showed an effect against staphylococci (MIC 1.0 
µg/ml for clotrimazole and miconazole as part of creams, MIC 1.6 µg/ml for miconazole nitrate 
alone and MIC 1.0 µg/ml for econazole nitrate alone). 
Activity against S. pyogenes was variable. Lamisil® 1% cream had the strongest effect, with a MIC 
of 10 µg/ml for terbinafine as part of the cream while terbinafine hydrochloride alone did not have 
any effect. 
There was no effect on E. coli for any of the antifungal formulations or substances. 
No effect against E. coli was detected for the formulations Canesten®, Daktar® or Daktacort®.  The 
possible effect of the azoles against E. coli was not determined because at 50 µg/ml the 
concentration of the solvent DMF (used to dissolve the substances before added to the agar) is 5%. 
MIC for DMF against E. coli is 5%.  
 
One aim of this investigation was to test whether base components of a formulation had additive or 
synergistic effects with the active substance of that formulation. Our data does not support the 
presence of such effects. MIC values for the active substance as part of a formulation and for the 
same substance tested separately were roughly the same (Table X). There were two exceptions to 
this, miconazole and terbinafine, respectively, which will be discussed in the following. 
 
• The lack of acitivity of miconazole in Daktar® and Daktacort® (MIC 1000 µg/ml) against C. 
albicans while miconanzole nitrate alone appeared effective (MIC 3.1 µg/ml) was an 
unexpected finding.  A possible explanation for this discrepancy could be interactions 
between cream and agar components inhibiting the effect of miconazole. It is also noted that 
glucocorticoids have been reported to inhibit the effect of some antimicrobials in vitro [179]. 
High concentrations of glucocorticoids have been shown to protect yeasts, but not 
staphylococci, in vitro against the action of econazole nitrate [180]. A glucocorticoid-azole 
interaction may explain the high MIC for miconazole in Daktacort®, which is a combination 
of miconazole and hydrocortisone, but not the MIC of Daktar®, which does not contain any 
glucocorticoid.  
 
• Terbinafine as part of Lamisil® exhibited MIC 2000 µg/ml against C. albicans, while 
terbinafine hydrochloride alone had a MIC of 25 µg/ml. A possible explanation for this, as 
proposed for Daktar® and Daktacort®, could be conditions in the in vitro situation, such as 
interactions between cream and agar components. 
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Our results show an effect of azoles against staphylococci, both as part of formulations and as 
single substances. The members of the azole class of drugs are known to possess antibacterial 
properties against some gram-positive bacteria [181, 182]. Clotrimazole and econazole have been 
shown to be effective against Mycobacterium smegmatis and Streptomyces strains but not E. coli in 
vitro [183]. These bacteria contain P450 mono-oxygenases (P450s), some of which are homologues 
to 14α-sterol demethylase, the target enzyme of azoles. It can be speculated that the in vitro effect of 
azoles against S. aureus and S. epidermidis demonstrated in our study are mediated through 14α-
sterol demethylase homologues in staphylococci. 
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 C. albicans  E. coli  S. aureus  S. epidermidis  S. pyogenes 
 ASPC/AS  EC  ASPC/AS  EC  ASPC/AS EC  ASPC/AS EC  ASPC/AS EC 
Fucidin® 2%  
(fusidic acid) 
No effect No effect  No effect No effect  0.1 5.0  0.1 5.0  10 500 
Fusidic acid No effect -  No effect -  0.13 -  0.13 -  6.3 - 
 
Table XI. Minimal inhibitory concentration (MIC) for antibiotic cream and substance. MIC expressed as µg/ml of active substance as part of cream 
(ASPC)a, entire cream (EC) and active substance alone (AS). 
a
 MIC of active substance as part of cream (ASPC) is calculated as the concentration of active substance in the cream multiplied by MIC for the entire 
cream. Modified from Alsterholm et al [184] (= paper III) with permission from the publisher. 
 
 C. albicans  E. coli  S. aureus  S. epidermidis  S. pyogenes 
 ASPC/AS EC  ASPC/AS EC  ASPC/AS EC  ASPC/AS EC  ASPC/AS EC 
Canesten® 1%  
(clotrimazole) 
10 1000  No effect No effect  1.0 100  1.0 100  500 50000 
Daktar® 2%  
(miconazole) 
1000 50000  No effect No effect  1.0 50  1.0 50  1000 50000 
Daktacort®  
(miconazole)  
1000 50000  4000 200000  1.0 50  1.0 50  1000 50000 
Miconazole nitrate  3.1 -  -b -  1.6 -  1.6 -  25 - 
Lamisil® 1%  
(terbinafine) 
2000 200000  No effect No effect  No effect No effect  2000 200000  10 1000 
Terbinafine HCl 25 -  -b -  No effect -  No effect -  No effect - 
Econazole nitrate 3.1 -  -b -  1.0 -  1.0 -  25 - 
Ketoconazole 3.1 -  -b -  25 -  13 -  -c - 
 
Table XII. Minimal inhibitory concentration (MICs) for antifungal creams and substances. MIC expressed as µg/ml of active substance as part of 
cream (ASPC)a, entire cream (EC) and active substance alone (AS). 
a
 MIC of active substance as part of cream (ASPC) is calculated as the concentration of active substance in the cream multiplied by MIC for the  entire 
cream.b MIC 50 µg/ml. At 50 µg/ml of miconazole nitrate, terbinafine HCL, econazole nitrate and ketoconazole there is 5% DMF in agar. MIC for 
DMF against E.coli is 5%. c MIC 50 µg/ml. At 50 µg/ml of ketoconazole there is 5% ethanol in agar. MIC for ethanol against S. pyogenes is 5%. 
Modified from Alsterholm et al [184] (= paper III) with permission from the publisher. 
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Corticosteroid formulations 
The corticosteroid creams showed high MICs against all microbes. In some cases there was still 
growth of microbes on agar plates with 20% (w/v) of cream (Table XIII). This was not unexpected. 
Still it was important to explore any potential antimicrobial effects of preservatives or other 
additives in these formulations. 
 
Corticosteroid formulations with antiseptic agent 
Corticosteroid creams with antiseptic agents showed an effect on all microbes tested (Table XIV). 
Betnovat® with chinoform (betamethasone with clioquinol) had similar activity against all microbes 
with the exception of S. pyogenes (MIC 15 µg/ml against C. albicans, E. coli, S. aureus and S. 
epidermidis and MIC 150 µg/ml against S. pyogenes, for clioquinol as part of the cream). 
Clioquinol tested alone had comparable effects. At 50 µg/ml of clioquinol no growth of S. pyogenes 
was seen. However, at 50 µg/ml of clioquinol there was 5% ethanol in the agar and MIC for ethanol 
against S. pyogenes was 5%, thus the true effect of clioquinol against S. pyogenes was not 
determined. 
Kenacutan® (triamcinolone with halquinol) was similarly effective against all microbes (MIC 7.5 
µg/ml for halquinol as part of the cream). MIC of Kenacutan® against S. pyogenes was not 
determined because this cream was discontinued during the study. 
 
Antiseptic formulation 
The antiseptic cream Microcid® 1% (hydrogen peroxide) had effect primarily on S. aureus (MIC 
1.0 µg/ml for hydrogen peroxide as part of the cream and 100 µg/ml for the entire cream) and S. 
epidermidis (MIC 0.5 µg/ml for hydrogen peroxide as part of the cream and 50 µg/ml for the entire 
cream) with weaker activity against E. coli, S. pyogenes and C. albicans (Table XV). 
 
The corticosteroids with antiseptic agents and the hydrogen peroxide cream Microcid® were the 
formulations with the widest species-related range of activity (Table X). In constant effort to limit 
the use of antibiotics, non-resistance-promoting antiseptic formulations with activity against 
bacteria and yeasts can be very useful in the treatment of superficial skin infections and in 
secondarily infected skin diseases. Betnovat® with chinoform and Kenacutan® had MICs of a 
magnitude which are probably reached in vivo. It is unfortunate that Kenacutan® is no longer 
available. 
Our results showed in vitro activity of Microcid® against the staphylococci but less so against S. 
pyogenes and E. coli and the effect was even weaker against C. albicans. The MIC for hydrogen 
peroxide as part of Microcid® cream was 500 µg/ml against C. albicans. This is equivalent to 0.05 g 
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cream/ml and it is conceivable that a concentration of that magnitude can be reached in vivo by 
applying a relatively modest amount of cream. This line of thought demonstrates the difficulty of 
interpreting and extrapolating in vitro data to the in vivo situation. Specifically, it is hard to 
transform a MIC-value obtained with the agar dilution assay into suggestions on the amount of 
cream needed to be applied in order to reach a similar concentration on the skin. The in vitro results 
of our study indicate that hydrogen peroxide preparations can be useful. The drawbacks of 
hydrogen peroxide are short time of action because of a high degradation rate and local irritation. 
Formulations need to stabilize as well as release hydrogen peroxide in order to be effective in vivo 
[150].  
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 C. albicans  E. coli  S. aureus  S. epidermidis  S. pyogenes 
 ASPC EC  ASPC EC  ASPC EC  ASPC EC  ASPC EC 
Betnovat® 
(betamethasone) 
200 200000  No effect No effect  No effect No effect  No effect No effect  100 100000 
Emovat® 0.05% 
(clobetasone butyrate) 
100 200000  100 200000  100 200000  50 100000  100 200000 
Dermovat® 0.05% 
(clobetasol) 
50 100000  100 200000  100 200000  100 200000  50 100000 
Hydrokortison CCS® 1% 
(hydrocortisone) 
2000 200000  No effect No effect  No effect No effect  2000 200000  500 50000 
 
Table XIII. Minimal inhibitory concentrations (MICs) for corticosteroid creams. MIC expressed as µg/ml of active substance as part of cream (ASPC)a 
and for the entire cream (EC). 
a
 MIC of active substance as part of cream (ASPC) is calculated as the concentration of active substance in the cream multiplied by MIC for the entire 
cream.  
Modified from Alsterholm et al [184] (= paper III) with permission from the publisher. 
 
 
 
 C. albicans  E. coli  S. aureus  S. epidermidis  S. pyogenes 
 ASPC/AS EC  ASPC/AS EC  ASPC/AS EC  ASPC/AS EC  ASPC/AS EC 
Betnovat® with chinoform 
(clioquinol) 
15 500  15 500  15 500  15 500  150 5000 
Clioquinol 6.3 -  13 -  6.3 -  6.3 -  -b - 
Kenacutan® (halquinol) 7.5 1000  7.5 1000  7.5 1000  7.5 1000  -c -c 
 
Table XIV. Minimal inhibitory concentrations (MICs) for corticosteroid creams with antiseptic agent. MIC expressed as µg/ml of active substance as 
part of cream (ASPC)a and for the entire cream (EC). 
a
 MIC of active substance as part of cream (ASPC) is calculated as the concentration of active substance in the cream multiplied by MIC for the entire 
cream. b MIC 50 µg/ml. At 50 µg/ml of clioquinol there is 5% ethanol in agar. MIC for ethanol against S. pyogenes is 5%. c Not investigated because 
Kenacutan® was taken off the market during this work.  
Modified from Alsterholm et al [184] (= paper III) with permission from the publisher. 
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 C. albicans  E. coli  S. aureus  S. epidermidis  S. pyogenes 
 ASPC EC  ASPC EC  ASPC EC  ASPC EC  ASPC EC 
Microcid® 1% (hydrogen peroxide) 500 50000  50 5000  1.0 100  0.50 50  50 500 
 
Table XV. Minimal inhibitory concentration (MIC) for antiseptic cream. MIC expressed as µg/ml of active substance as part of cream (ASPC)a and for 
the entire cream (EC). 
 
a
 MIC of active substance as part of cream (ASPC) is calculated as the concentration of active substance in the cream multiplied by MIC for the entire 
cream. 
Modified from Alsterholm et al [184] (= paper III) with permission from the publisher.
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Benefits and hazards with antiseptics 
The results of the study highlight the potential usefulness of azoles and antiseptic preparations.  
While skin bacteria, especially S. aureus, have developed resistance to various antibiotics, the 
topical azoles and allylamines used against dermatophytes and yeast infections have been 
prescribed extensively with less development of clinically relevant resistance among fungi [185, 
186]. Therefore it was interesting to explore any antibacterial effects of antifungals. We find that the 
azoles are effective against S. aureus and S. epidermidis in vitro. If this activity is present in vivo as 
well it could be beneficial in the treatment of mixed superficial skin infections. 
To be able to replace or complement antibiotics with topical antiseptics is an appealing concept. In 
contrast with the targeted action of antibiotics, antiseptics are not as pharmacologically precise and 
act on multiple cellular targets making it harder for microbes to evade their damaging effects. It can 
be argued that increased proper use of antiseptics for localized superficial skin infections could 
decrease the use of antibiotics, thus minimizing selective pressure on bacterial strains.  
There is however concern that the use of biocides in health care, households and in industrial 
settings can promote resistance to antiseptics and contributes to the selection of antibiotic-resistant 
strains [146]. For instance, increased antiseptic MICs, due to the presence of the qacAB family of 
genes encoding multi-drug efflux pumps, have been described for MRSA strains [187]. These efflux 
pumps can confer resistance to chlorhexidine and other antiseptics. The qacAB family of genes is 
present predominantly on multi-resistance plasmids, and has been found in methicillin-sensitive S. 
aureus and CoNS as well. The significance of this with regards to clinical effect (e.g. hand 
disinfectants) and the ecological consequences (cross-resistance with antibiotics and selection for 
resistant strains) remains to be discovered.  
Another important consideration is the risk of allergic reactions to antiseptics. For instance, 
chlorhexidine can provoke life-threatening anaphylactic reactions, even after application on 
unbroken skin [147-149]. 
 
Conclusion 
Microbes are believed to trigger, exacerbate and/or sustain inflammatory skin disease, such as AD 
(discussed in paper IV), balanoposthitis and seborrhoeic dermatitis (discussed in paper I). Treatment 
of these and other skin diseases can require intermittent use of antibiotics and antifungals in 
addition to anti-inflammatory agents. We are facing a global rapid dissemination of multi-resistant 
bacteria. Therefore, dermatologists and all other health care professionals need to carefully consider 
every prescription of antibiotics and make us of antiseptic alternatives including the antimicrobial 
potential of already existing topical skin pharmaceuticals. 
This study highlights the broad in vitro antimicrobial effect of the currently available clioquinol and 
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hydrogen peroxide formulations and of the discontinued halquinol formulation. The azole class of 
antifungal formulations have an anti-staphylococcal effect. 
The development of new antiseptic and antibiotic topical preparations is an important task for the 
future. Responsible use of existing and future formulations is essential for the successful 
management of skin infections. 
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PAPER IV 
 
The variations in S. aureus colonization (measured with qualitative and quantitative culture and 
PFGE) and disease severity (measured with objective SCORAD index) were described over a 5-
month period in twenty adult patients with moderate to severe AD.  
 
At total of 21 patients (eleven men and ten women) participated in the study. Nineteen patients 
attended all three visits. Patient number 10 attended the first visit but declined further participation. 
Patient number 12 was unable to attend the second visit due to a traumatic elbow injury but 
attended the first and third visit. 
The objective SCORAD index showed that 19 patients (90%) exhibited moderate AD at one or 
more visits, for some fluctuating to mild (6/19) or severe (8/19). One patient had consistently mild 
AD and one patient had consistently severe AD during follow-up (Table I*). 
 
S. aureus colonization rate on lesional and uninvolved skin 
The proportion of patients colonized with S. aureus at least once during follow-up was 71% for 
lesional skin and 90% for uninvolved skin (Table II). 
 
S. aureus density on lesional and uninvolved skin 
The mean S. aureus density for the patients was higher on lesional skin than on uninvolved skin at 
all visits (p = 0.04, p = 0.02 and p = 0.02 for visits 1, 2 and 3, respectively) (Table II, Figure 1). 
Higher density of S. aureus on lesional skin corresponded to more severe disease, measured as 
objective SCORAD index (visit 1, p = 0.0003, R2 = 0.49; visit 2, p = 0.0003, R2 = 0.52; visit 3, 
p = 0.004, R2 = 0.35) (Figure 2). 
 
Number of body sites colonized with S. aureus 
Five different body sites were sampled for S. aureus at each visit; lesional skin, uninvolved skin, the 
anterior nares, tonsils and perineum. The number of body sites colonized with S. aureus was 
positively correlated with the objective SCORAD index (p = 0.007, R2 = 0.46) (Figure 3). Statistical 
analysis was made with generalized least square regression for all observations from all visits and 
with linear regression for all observations from each visit separately (data not shown) with similar 
result.  
 
 
*Paper IV is currently in manuscript. For tables and figures the reader is referred to the manuscript. 
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Variations in carriage of S. aureus strain 
PFGE was performed on all S. aureus isolates from lesional skin, the anterior nares and perineum (n 
= 94) and a majority of isolates from uninvolved skin (n = 25). Low counts of S. aureus on 
uninvolved skin in the absence of S. aureus on lesional skin were not typed.  
There were few intra-individual changes in carriage of strain during follow-up. Eleven patients 
(11/20, 55%) were persistent carriers of a specific strain on lesional skin. Persistent carriage was 
defined as same S. aureus strain at three visits or same strain at two visits and S. aureus-negative at 
remaining visit. Seven patients (7/20, 35%) were non-carriers of S. aureus on lesional skin (5/7) or 
intermittent carriers (2/7). Non-carriage was defined as S. aureus-negative on lesional skin at all 
three visits. Intermittent carriage was defined as S. aureus-positive on lesional skin with low counts 
at one visit, negative at remaining visits (Table IV). The mean objective SCORAD index was 
significantly higher among persistent carriers than among non- and intermittent carriers (38.0 vs 
17.2, p = 0.002) (Figure 4). 
 
 
In order to understand the clinical influence of S. aureus in AD it is important to investigate the 
temporal variations in colonization in relation to disease severity. Flare-ups of AD are often 
associated with S. aureus super-infection and one treatment strategy is the use of topical 
antimicrobial agents and oral antibiotics [92]. Despite the strong link between flare-ups of AD and 
S. aureus super-infection, the importance of S. aureus colonization in AD pathogenesis and the 
impact of colonization in patients with clinically non-infected AD remain controversial. 
AD is not just a disease affecting children and teenagers but often persists in later life why research 
should focus on adults as well [188]. The temporal shift in S. aureus colonization in relation to the 
severity of AD has, to our knowledge, rarely been described in adults. 
 
The patients participating in this study were adults with moderate to severe AD which they felt was 
satisfactorily managed with emollients and topical corticosteroids. They were not treated with 
topical or oral antimicrobials, phototherapy or oral immunomodulators during follow-up.  
Phototherapy was excluded because UV-light affects the microbial flora on atopic skin, including S. 
aureus, and decreases disease severity [97-99]. We chose to conduct the study during the first six 
months of the year (January to mid-June 2011) when the climate in Sweden offers little outdoor 
living and UV-exposure. The UV-exposure that can occur in late spring and early summer did not 
affect mean objective SCORAD index or mean number of S. aureus isolates (no statistically 
significant difference between visit 1, 2 and 3, data not shown). 
Patients treated with immunomodulating drugs (e.g. cyclosporine or oral corticosteroids) were not 
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included since immunomodulation might influence the composition of the skin microbiome, 
potentially complicating the interpretation of data. 
 
The data in this study represents the normal variations in disease severity and life circumstances for 
adult patients with moderate to severe AD. There were only two flare-ups of AD during follow-up. 
Those flare-ups required anti-staphylococcal antibiotic treatment (patient number 17 and patient 
number 21). In addition, there was a one antibiotic treatment for a post-traumatic soft tissue 
infection and one short term prophylactic treatment after minor skin surgery (patient number 12 and 
patient number18). Two of the patients were colonized with a new S. aureus strain on lesional skin 
after antibiotic treatment (patient number 18 and patient number 21). 
 
The patients in this study were colonized with S. aureus on lesional skin, uninvolved skin, in the 
anterior nares, tonsils and perineum to a much higher extent than the general population. In the 
general population, S. aureus carriage rates on different body sites are highly variable and 
influenced by nasal carriage status. In nasal non-carriers the rate of colonization on different body 
sites averages 15% with the hands, forearm and the perineum being the most common site of 
carriage. In persistent nasal carriers the rate of colonization averages 40% with colonization of the 
hands in 90%, the forearm in 45% and the perineum in 60% of cases [12]. The colonization rates on 
different body sites among the patients in this study were similar to those of persistent nasal carriers 
in the general population even though 24% (5/21) of patients were non-carriers in the anterior nares 
during follow-up (Table III, Table IV).   
 
It is well known that nasal colonization is a risk factor for staphylococcal skin infection [12]. We 
propose that nasal colonization is a risk factor for colonization/recolonization of atopic skin as well 
and this has been indicated by others [189]. It is also possible that atopic skin can serve as a 
significant reservoir for S. aureus, equally or more important than the anterior nares, with 
colonization of the skin influencing the colonization of the anterior nares rather than the reverse. An 
early study of colonization and infection with S. aureus in AD found nasal carriage in 84% of 
patients, comparable to 53-67% in this study [190]. Interestingly, five patients in our study (5/21, 
24%) carried one S. aureus strain in the anterior nares and another strain on lesional skin at one or 
several visits, demonstrating that nasal carriage does not always dictate which strain is carried on 
the skin. 
 
Persistent carriers of S. aureus on lesional skin had significantly higher mean objective SCORAD 
index than non-/intermittent carriers. This data support previous findings that S. aureus carriage on 
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lesional skin is associated with more severe AD [93, 191-193]. In addition, linear regression 
analysis showed that patients with more severe AD had higher density of S. aureus on lesional skin 
and carried S. aureus on multiple body sites. 
 
This study shows that the patients with the most severe AD were persistent carriers of the same 
strain on lesional skin during follow-up. They were also carriers of the same strain at multiple other 
body sites.  It has been proposed that colonization with a new S. aureus strain could provoke an 
exacerbation of AD by triggering the immune system [191]. Atopic skin obviously provides a 
beneficial environment for S. aureus and the concept of frequent recolonization with a new strain is 
not inconceivable. The results of this study (although follow-up was short) do not support 
colonization with a new S. aureus strain as a prominent trigger of disease activity.  In fact, even 
though there were large intra-individual fluctuations in SCORAD indices, a change of S. aureus 
strain was a rare event for any of the participants. The results indicate that variations in AD 
intensity, at least in the absence of acute flare-ups and antibiotic treatment, are associated with a 
change in S. aureus density on lesional skin but not necessarily with a change of strain. 
 
Is S. aureus a primary trigger of dermatitis or is colonization a secondary phenomenon due to the 
fact that the altered skin barrier in AD provides a beneficial environment for S. aureus? The 
question remains controversial. Wherever truth lies, the abundance of virulence factors associated 
with S. aureus supports a role for this fascinating microbe as a driving force in the skin 
inflammatory response. Reducing the amount of S. aureus on the skin could very well be beneficial 
for AD severity although this is still not conclusively demonstrated in a large randomized clinical 
trial. It is important to consider that anti-staphylococcal treatment might be effective for patients 
who are persistent S. aureus carriers but less so for intermittent carriers. We believe that persistent 
carriers need to be identified in the inclusion process of future clinical trials. There is a possibility 
that AD patients who are persistent carriers of one S. aureus strain in high numbers and on multiple 
sites could benefit from anti-staphylococcal treatment in the absence of clinical infection. Changes 
in the skin microbiome before, during and after disease flares have recently been described in 
children with AD using 16S ribosomal RNA bacterial gene sequencing [194]. The authors show that 
microbial diversity on lesional skin was dramatically reduced during flare-ups but changed towards 
higher diversity post-treatment. Flare-ups were characterized by a build-up to high numbers of one 
species, typically staphylococci, while an increasing proportion of Streptococcus, 
Propionibacterium, Corynebacterium and other species were observed following therapy. We 
suggest that intermittent treatment with topical antimicrobials could prevent the domination of S. 
aureus and promote microbial diversity on the skin. This could potentially reduce overall disease 
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severity and number of flare-ups for those AD patients who are persistent S. aureus carriers on 
lesional skin. Preferably, antiseptics should be used since it is important not to further increase the 
use of topical or oral antibiotics. As with all cutaneous application the risk for allergic reactions 
(contact dermatitis and anaphylaxis) has to be considered when designing new treatment strategies. 
If intermittent use of antiseptics proves effective it could be an antibiotic-sparing treatment strategy. 
This area of research warrants further exploration.  
 
Conclusion 
We describe the temporal shift in S. aureus density and strain distribution along with changes in 
disease severity in adult patients with AD. Colonization with S. aureus on lesional skin is associated 
with more severe disease. Even in the absence of acute flare-ups the objective SCORAD index 
varies greatly. In our study, these variations occur without a shift in strain but with concomitant 
changes in S. aureus density on lesional skin. The data implies that intermittent anti-staphylococcal 
treatment could be beneficial for persistent S. aureus carriers by reducing bacterial density, breaking 
the reign of a single S. aureus strain and thereby promote a more diverse microbiome. Clinical trials 
investigating the effects of anti-staphylococcal treatment in AD patients persistently colonized with 
S. aureus are needed. 
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CONCLUSION OF PAPER I-IV 
 
Patients with balanoposthtitis have a significantly higher frequency of microbes in the area of the 
prepuce and glans penis compared to healthy controls. S. aureus was found in 19% of 
balanoposthitis patients but not at all in the control group. An increase in C. albicans in 
balanoposthtitis, previously described by others, was not confirmed. Clinical findings did not 
predict presence of specific microbes. There was no association between balanoposthtitis and 
seborrhoeic dermatitis or psoriasis. The primary therapeutic target in mild to moderate cases of 
balanoposthtitis without overt signs of infection should be to decrease inflammation with a mild 
topical corticosteroid (group I or II). The addition of antimicrobial agents to the topical preparation 
can reduce microbial load and further help to decrease inflammation.  
 
FRSA was a common cause of impetigo, especially bullous impetigo, in the period studied. It was a 
relatively rare finding in secondarily infected AD. Rates of FRSA isolation from impetigo and 
secondarily infected AD did not increase in the period studied. There is strong evidence that the 
community pattern of topical fusidic acid use influences the proportion of FRSA isolates cultured 
from patients. Management of impetigo and other SSTIs is possible without topical fusidic acid 
formulations and use should be avoided. 
 
Topical skin pharmaceuticals with clioquinol, halquinol and hydrogen peroxide have a broad 
antimicrobial effect in vitro. The azole class of topical antifungal formulations have an anti-
staphylococcal effect in vitro. These effects, when present in vivo, should be used when appropriate 
to avoid unnecessary antibiotic treatment of limited superficial skin infections. In view of increasing 
antibiotic resistance the development of new antiseptic and antibiotic topical preparations is an 
important task for the future. Responsible use of existing and future formulations is essential for the 
successful management of skin infections. 
 
In adults with AD, variations in disease severity were positively correlated with S. aureus density on 
lesional skin, number of body sites colonized and persistent carriage of the same S. aureus strain. 
The data suggest that patients with this pattern of S.aureus colonization might benefit from anti-
staphyloccoccal interventions even in the absence of signs of infection.  
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FUTURE PERSPECTIVES 
 
Our current practice is to treat mild to moderate balanoposthitis with a topical hydrocortisone-
miconazole combination. It would be interesting to test this treatment against hydrocortisone alone 
and miconazole alone in a double blind study. Results could determine if anti-inflammatory 
interventions, anti-microbial interventions or a combinantion of both are the most effective. 
 
There is a continuous discussion regarding the transmission of Candida between partners in 
heterosexual relationships. Evidence to support male to female sexual transmission of Candida as a 
clinically significant cause of recurrent vulvovaginal candididas is lacking [195-197]. At the same 
time, the 2008 U.K. National Guidelines on the Management of Balanoposthtitis state that there is a 
high rate of candidal infection in sexual partners of patients with Candida balanoposthitis and that 
these partners should be offered screening [71]. The fact that transmission of Candida species from 
men to women seem to be of limited clinical importance for recurrent vulvovaginal candidiasis does 
not necessarily mean that vulvovaginal candidiasis will not increase the risk for balanoposthitis. We 
have found no studies describing the prevalence of Candida balanoposhtitis in partners of women 
with recurring vulvovaginal candidiasis. A prospective study of men in monogamous relationships 
with women suffering from recurrent vulvovaginal candidiasis could help shed light on possible 
effects for these men. 
 
To complement the yearly FRSA-surveillance from ResNet it would be interesting to perform a new 
culture-based study at the Department of Dermatology at Sahlgrenska University Hospital. A 
suggested design would be to prospectively collect cultures from all patients with impetigo and AD 
(this time including clinically non-infected AD as well) during three months. 
 
The impact of S. aureus colonization on AD deserves further investigation. We plan to analyze for 
virulence factors with polymerase chain reaction in the isolates which have already been collected 
and typed for strain specificity.  
An exciting prospect would be a late follow-up of the patients described in paper IV.  What shifts 
occur in the characteristics of S. aureus colonization and AD severity over longer periods of time? 
Ultimately, a randomized controlled trial investigating the effect of an anti-staphylococcal 
intervention on AD severity in patients with significant and persistent S. aureus carriage could 
prove rewarding. 
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POPULAR SCIENCE SUMMARY IN SWEDISH 
 
KOLONISATION OCH INFEKTION MED STAFYLOKOCKER OCH ANDRA 
MIKROORGANISMERS VID HUDSJUKDOM 
 
Introduktion 
Mikroorganismer såsom bakterier och svampar koloniserar ständigt vår hud. Kolonisation innebär 
att mikroorganismer lever på huden utan att orsaka skada. De utgör dessutom ett skydd genom att 
hindra sjukdomsframkallande bakterier och svampar från att få fäste och ge upphov till en infektion. 
Koloniserande mikroorganismer tros kunna underhålla och försämra hudsjukdomar som uppstått av 
annat skäl.  
Bakterien Staphylococcus aureus (S. aureus) kan kolonisera huden men även ge upphov till 
hudinfektion. Studierna som ingår i den här avhandlingen har undersökt förekomst och betydelse av 
S. aureus och andra mikroorganismer vid hudsjukdom. 
 
Artikel I 
Den första studien har undersökt förekomsten av mikroorganismer på ollon och förhud vid balanit, 
en eksemliknande reaktion på penis som drabbar de flesta män. Överdrivet tvättande och skav vid 
samlag är vanliga orsaker. Tidigare studier har visat att infektion med svampen Candida albicans 
(C. albicans) kan vara en orsak. Studien som presenteras i avhandlingen visar att mikroorganismer 
är vanligare på ollon och förhud hos patienter med balanit än hos en frisk kontrollgrupp. Framförallt 
förekom S. aureus ofta (19%) vid balanit men inte alls hos friska. Svamp var inte vanligare vid 
balanit i denna studie.  
Slutsats: Patienter med balanit är koloniserade med mikroorganismer, framförallt S. aureus, oftare 
än friska och det kan underhålla och förstärka eksemreaktionen på ollon och förhud. Behandlingen 
bör inriktas på att minska eksemreaktionen och mängden mikroorganismer med en mild 
kortisonkräm med bakterie- och svampdödande tillsats. 
 
Artikel II 
Den andra studien har undersökt vilka bakterier som växer på huden vid hudinfektionen impetigo 
(svinkoppor) och vid infekterat eksem. S. aureus var den vanligaste bakterien och hittades i 76-93% 
av fallen. De S. aureus som hittades var i varierande utsträckning motståndskraftiga mot 
antibiotikakräm innehållande fusidin som tidigare använts mycket vid behandling av impetigo. 75% 
av S. aureus var motståndskraftiga mot fusidin vid blåsbildande impetigo, 32 % vid icke-
blåsbildande impetigo och 6.1% vid infekterat eksem.  
Slutsats: S. aureus motståndskraftiga mot fusidin är en vanlig orsak till impetigo men är relativt 
ovanliga vid infekterat eksem. Användning av fusidinkräm kan ge ökning av motståndskraftiga S. 
aureus och bör undvikas. 
 
Artikel III 
Den tredje studien har undersökt den bakterie- och svampdödande effekten hos vanligt 
förekommande hudläkemedel (krämer). Krämerna har testats genom att gjutas in i odlingsplattor 
där olika mikroorganismer som kan finnas på huden fått växa. Krämer som innehöll substanserna 
clioquinol, halquinol och väteperoxid var effektiva mot många olika mikroorganismer. Azoler, som 
är svampläkemedel, hade dessutom effekt mot bakterier av typen stafylokocker, t ex S. aureus. 
Slutsats: Den bakterie- och svampdödande effekten hos nu tillgängliga läkemedel bör utnyttjas. 
Nya läkemedel i krämform som inte främjar utveckling av motståndskraft hos mikroorganismer 
behövs för att i framtiden behandla hudinfektioner. 
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Artikel IV 
Den fjärde studien har undersökt hur kolonisation med S. aureus på huden och andra ställen på 
kroppen varierar över tid hos vuxna patienter med eksem. Samtidigt har svårighetsgraden av 
eksemet mätts. De patienter som hade svårt eksem bar oftare S. aureus på den eksemdrabbade 
huden och hade tätare växt av S. aureus än patienter med lindrigare eksem. De bar också oftare S. 
aureus på frisk hud, i näsan och svalget. 
Slutsats: Det är viktigt att fortsätta studera samspelet mellan S. aureus kolonisation och 
svårighetsgrad av eksem för att avgöra det eventuella värdet av att behandla ner mängden S. aureus 
hos patienter med eksem. 
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